Bibliography 1. Anonymous US Congress Office of Technology Assessment, Impacts of Antibiotic-Resistant Bacteria. U.S.Government.Printing.Office,.Washington,D.C. -, 1995. 2. Anonymous 1995 Annual Data Report, The North American Pediatric Renal Transplant Cooperative Study. The.Emmes.Corp,.Potomac,MD. 76-85-85, 1995. 3. Anonymous Report of a working party of the British Society for Antimicrobial Chemotherapy. Diagnosis and management of peritonitis in continuous ambulatory peritoneal dialysis. Lancet i:845-848:845-848, 1987. 4. Abraham, G. Streptococcus pyogenes peritonitis associated with genital swelling and gastroenteritis caused by Cryptosporidium and Salmonella paratyphi B in an HIV infected patient on CAPD [letter]. Nephrol.Dial.Transplant. 10:140-141:140-141, 1995. 5. Agarwal, S., Goodman, N.L., and Malluche, H.H. Peritonitis due to Exophiala jeanselmei in a patient undergoing continuous ambulatory peritoneal dialysis. Am.J.Kidney Dis. 21:673-675:673-675, 1993. 6. Ahlmen, J., Edebo, L., Eriksson, C., Carlsson, L., and Torgersen, A.K. Fluconazole therapy for fungal peritonitis in continuous ambulatory peritoneal dialysis(CAPD): A case report. Perit.Dial.Intl. 9:79-80:79-80, 1989. 7. Ahlmen, J., Bronnestam, R., Eridsson, C., Torgersen, A.K., and Carlsson, L. Imipenem in the treatment of peritonitis during continuous ambulatory peritoneal dialysis (CAPD). Perit.Dial.Bull. 7:-, 1987. 8. Akl, K. and Milder, J.E. Ketoconazole treatment of candida peritonitis during continuous peritoneal dialysis. Pediatr.Infect.Dis. 3:487-:487, 1984. 9. Al-Wali, W., Baillod, R., Brumfitt, W., and et.al. Differing prognostic significance of infection and relapse in CAPD peritonitis. Nephrol.Dial.Transplant. 7:133-136:133-136, 1992. 10. Albin, H., Ragnaud, J.M., Demotes-Mainard, F., Vincon, G., Couzineau, M., and Wone, C. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. Eur.J.Clin.Pharmacol. 31:479-483:479-483, 1986. 11. Albin, H.C., Demotes-Mainard, F.M., Bouchet, J.L., Vincon, G.A., and Martin-Dupont, C. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 38:285-289:285-289, 1985. 12. Alexander, D., Gambertoglio, J., Barriere, S., Warnock, D., and Schoenfeld, P. Cefotaxime (C) pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). Perit.Dial.Bull. 35:225-225:225, 1984. 13. Alexander, S.R., Linblad, A.S., Nolph, K.D., and Novak, J.W. Pediatric CAPD/CCPD in the United States; a review of the experiences of the National CAPD Registry's pediatric patient population for the period of January 1, 1981, to August 31, 1986. Churchill.Livingstone,.New York. 231-235-235, 1990. 14. Alobaidi, H.M., Coles, G.A., Davies, M., and Lloyd, D. Host defense in continuous ambulatory peritoneal dialysis: the effect of dialysate on phagocyte function. Nephrol.Dial.Transplant. 1:16-21:16-21, 1986. 15. Amici, G., Grandesso, S., Mottola, A., Virga, G., Teodori, T., Maresca, M.C., and Bocci, C. Verticillium peritonitis in a patient on peritoneal dialysis. Am.J.Nephrol. 14:216-219:216-219, 1994. 16. Anwar, N., Merchant, M., Were, T., Tooth, A., Uttley, L., and Gokal, R. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. Perit.Dial.Int. 15:167-171:167-171, 1995. 17. Anwar, N., Strap, J.L., and Costerton, J.W. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob.Agents Chemother. 36(7):1347-1351, 1992. 18. Arvidsson, A., Alvan, G., Tranaeus, A., and Malmborg, A.S. Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. Eur.J.Clin.Pharmacol. 28:333-337:333-337, 1985. 19. Ashby, M.J., Neale, J.E., Knott, S.J., and Critchley, I.A. Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli. J.Antimicrob.Chemother. 33(3):443-452, 1994. 20. Bailie, G.R., Haqqie, S.S., Eisele, G., Gorman, T., and Low, C.L. Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis [see comments]. Perit.Dial.Int. 15:269-271:269-271, 1995. 21. Bailie, G.R. and Eisele, G. Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. J.Antimicrob.Chemother. 35:563-567:563-567, 1995. 22. Bailie, G.R. and Kane, M.P. Stability of drug additives to peritoneal dialysate. Perit.Dial.Int. 15:328-335:328-335, 1995. 23. Bailie, G.R., Eisele, G., Venezia, R.A., and et.al. Prediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitis. Clin.Pharmacokinet. 22:298-307:298-307, 1992. 24. Bailie, G.R., Morton, R., Ganguli, L., Keaney, M., and Waldek, S. Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated Gram-positive peritonitis? Nephron 46:316-318:316-318, 1987. 25. Bald, M., Rascher, W., Bonzel, K.E., and Müller-Wiefel, D.E. Pharmacokinetics of intraperitoneal cefotaxime in children with peritonitis undergoing continuous ambulatory peritoneal dialysis. Perit.Dial.Int. 10:311-313:311-313, 1990. 26. Banerji, C., Wheeler, D.C., and Morgan, J.R. Listeria monocytogenes CAPD peritonitis: failure of vancomycin therapy [letter]. J.Antimicrob.Chemother. 33:374-375:374-375, 1994. 27. Barbhaiya, R.H., Knupp, C.A., Pfeffer, M., and et.al. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 36:1387-1391:1387-1391, 1992. 28. Barza, M., Ioannidis, J.P.A., Cappelleri, J.C., and Lau, J. Single or multiple daily doses of aminoglycosides: a meta-analysis. B.M.J. 312:338-345:338-345, 1996. 29. Bastani, B., Freer, K., Read, D., Bailey, S., Sherman, R.A., Davis, M., Engels, D., and Westervelt, J. Treatment of Gram-positive peritonitis with two-intraperitoneal doses of vancomycin in continuous ambulatory peritoneal dialysis patients. Nephron 45:283-285:283-285, 1987. 30. Battista, C., Kane, M.P., Moon, D.G., and Bailie, G.R. Stability of ofloxacin in peritoneal dialysis solutions. Perit.Dial.Int. 15:72-74:72-74, 1995. 31. Beaman, M., Solaro, L., McGonigle, R.J.S., Michael, J., and Adu, D. Vancomycin and ceftazidime in the treatment of CAPD peritonitis. Nephron 51:51-55:51-55, 1989. 32. Beard-Pegler, M.A., Gabelish, C.L., Stubbs, E., and et.al. Prevalence of peritonitis-associated coagulase-negative staphylococci on the skin of continuous ambulatory peritoneal dialysis patients. Epidemiol.Infect. 102:365-378:365-378, 1989. 33. Benevent, D., Peyronnet, P., Lagarde, C., and Leroux-Robert, C. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Nephron 41:203-206:203-206, 1985. 34. Bennett-Jones, D.N., Russell, G.I., and Barrett, A. A comparison between oral ciprofloxacin and IP vancomycin and gentamicin in CAPD peritonitis. J.Antimicrob.Chemother. 26((suppl F):73-76, 1990. 35. Bennett-Jones, D., Wass, V., Mawson, P., Taube, D., Neild, G., Ogg, C., Cameron, J.S., and Williams, D.G. A comparison of intraperitoneal and intravenous/oral antibiotics in CAPD peritonitis. Perit.Dial.Bull. 7:31-33:31-33, 1987. 36. Benzakour, M., Lagarde, C., Benevent, D., Mounier, M., and Denis, F. Peritonitis during continuous ambulatory peritoneal dialysis. Treatment with pefloxacin: first results and pharmacokinetics. Nephron 50:175-176:175-176, 1988. 37. Bergamini, T.M., Peyton, J.C., and Cheadle, W.G. Prophylactic antibiotics prevent bacterial biofilm graft infection. J.Surg.Res. 52(2):101-105, 1992. 38. Bernardini, J., Piraino, B., Holley, J., Johnston, J.R., and Lutes, R. A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am.J.Kidney Dis. 27:695-700:695-700, 1996. 39. Bernardini, J., Lutes, R., Johnston, J.R., Holley, J.L., and Piraino, B. Randomized trial of rifampin versus mupirocin to prevent S. aureus infections in PD patients. Perit.Dial.Int. 15:S17-:S17, 1995. 40. Bernardini, J., Holley, J.L., Johnston, J.R., Perlmutter, J.A., and Piraino, B. An analysis of ten-year trends in infections in adults on continuous ambulatory peritoneal dialysis (CAPD). Clin.Nephrol. 36(1):29-34, 1991. 41. Bernardini, J., Piraino, B., and Sorkin, M. Analysis of continuous ambulatory peritoneal dialysis-related Pseudomonas aeruginosa infections. Am.J.Med. 83:829-832:829-832, 1987. 42. Bille, M. Medical treatment of staphylococcal infective endocarditis. Eur.Heart J. 16(Suppl B):80-83, 1995. 43. Bint, A.J., Finch, R.G., Gokal, R., Goldsmith, H.J., Junor, B., and Oliver, D. Diagnosis and management of peritonitis in continuous ambulatory peritoneal dial. Lancet i:845-848:845-848, 1987. 44. Bint, A.J., Constable, J., and Patton, K.R. Studies with ceftazidime in peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Proceedings.of.the.22nd.Interscience.Conference.on.Antimicrobial.Agents and.Chem. 209-209-209, 1982. 45. Bint, A.J., Gokal, R., Patton, K.R., Sornes, S., and Ward, M.K. Peritonitis in continuous ambulatory peritoneal dialysis: laboratory and clinical studies with cefuroxime. Royal.Society.of.Medicine International.Congress.and.Symposium,. 38:173-177:173-177, 1980. 46. Blackwell, B.G., Leggett, J.E., Johnson, C.A., Zimmerman, S.W., and Craig, W.A. Ampicillin and sulbactam pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD). Perit.Dial.Int. 10(3):221-226, 1990. 47. Blaser, J., Vergeres, P., Widner, A.F., and Zimmerli, W. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob.Agents Chemother. 39(5):1134-1139, 1995. 48. Blevins, R.D., Halstenson, C.E., Salem, N.G., and Matzke, G.R. Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 25:603-606:603-606, 1984. 49. Bliss, M., Sayerson, M., Arnold, T., Logan, T., Michael, U.F., and Jones, W. Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 29:649-653:649-653, 1986. 50. Blowey, D.L., Warady, B.A., and McFarland, K.S. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. Adv.Perit.Dial. 10:297-299:297-299, 1994. 51. Boeschoten, E.W., Rietra, P.J.G.M., Krediet, R.T., Visser, M.J., and Arisz, L. CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J.Antimicrob.Chemother. 169:789-797:789-797, 1985. 52. Bonati, M., Traina, G.L., Rosina, R., and Buniva, G. Pharmacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairment. J.Antimicrob.Chemother. 21:29-37:29-37, 1988. 53. Bonnardeaux, A., Ouimet, D., Galarneau, A., Falardeau, M., Cardinal, J., Nolin, L., and Houde, M. Peritonitis in continuous ambulatory peritoneal dialysis: impact of a compulsory switch from a standard to a Y-connector system in a single North American center. Am.J.Kidney Dis. XIX:364-370:364-370, 1992. 54. Bouchet, J.L., Aparicio, M., Vincon, G., and et.al. Pharmacokinetic considerations for treatment of bacterial peritonitis during continous ambulatory peritoneal dialysis. Contrib.Nephrol. 89:96-107:96-107, 1991. 55. Bowley, J.A., Pickering, S.J., Scantlebury, A.J., Ackrill, P., and Jones, D.M. Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. J.Antimicrob.Chemother. 21:133-139:133-139, 1988. 56. Bowman, R.A., Medley, A.S., and Khartaghisu, K.T. Limulus amoebocyte lysate assay in the diagnosis of peritonitis in patients receiving continuous ambulatory peritoneal dialysis. J.Clin.Path. 45:72-74:72-74, 1992. 57. Boyce, N.W., Wood, C., Napier, M.T., Kerr, P., and Atkins, R.C. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis - a prospective, randomized comparison of intermittent v continuous therapy. Am.J.Kidney Dis. 12:304-306:304-306, 1988. 58. Boyce, S.T., Supp, A.P., Warden, G.D., and Holder, I.A. Attachment of an aminoglycoside, amikacin, to implantable collagen for local delivery in wounds. Antimicrob.Agents Chemother. 37:1890-1895:1890-1895, 1993. 59. Brauner, L., Kahlmeter, G., Lindholm, T., and Simonsen, O. Vancomycin and netilmicin as first line treatment of peritonitis in CAPD patients. J.Antimicrob.Chemother. 15:751-758:751-758, 1985. 60. Brier, M.E. and Aronoff, G.R. Initial intraperitoneal therapy for CAPD peritonitis: the Network 9 Peritonitis Study. Adv.Perit.Dial. 10:141-143:141-143, 1994. 61. Brouard, R., Tozer, T.N., Merdjan, H., Guillemin, A., and Baumelou, A. Transperitoneal movement and pharmacokinetics of cefotiam and cefsulodin in patients on continous ambulatory peritoneal dialysis. Clin.Nephrol. 30:197-206:197-206, 1988. 62. Brown, A.L., Stephenson, J.R., Baker, L.R., and et.al. Epidemiology of CAPD associated peritonitis caused by coagulase negative staphylococci: comparison of strains isolated from hands, abdominal Tenckhoff catheter exit site and peritoneal fluid. Nephrol.Dial.Transplant. 6:643-648:643-648, 1991. 63. Brown, M.R. and Gilbert, P. Sensitivity of biofilms to antimicrobial agents. J.Appl.Bacteriol. 74(Suppl):87S-97S, 1993. 64. Browning, M.J., Holt, H.A., White, L.O., Chapman, S.T., Banks, R.A., Reeves, D.S., and Yates, R.A. Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis. J.Antimicrob.Chemother. 18:103-106:103-106, 1986. 65. Buggy, B.P. Culture methods for continuous ambulatory peritoneal dialysis associated peritonitis. Clin.Microbiol.Newsl. 8:12-14:12-14, 1986. 66. Buggy, B.P., Schaberg, D.R., and Swartz, R.D. Intraleukocyte sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. Am.J.Med. 76:1035-1040:1035-1040, 1984. 67. Bunke, C.M., Aronoff, G.R., Brier, M.E., Sloan, R.S., and Luft, F.C. Tobramycin kinetics during continuous ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 34:110-116:110-116, 1983. 68. Bunke, C.M., Aronoff, G.R., Brier, M.E., Sloan, R.S., and Luft, F.C. Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 33:66-72:66-72, 1983. 69. Bunke, M., Brier, M.E., Golper, T.A., and representing the Academic Committee of Network #9 Pseudomonas peritonitis in peritoneal dialysis patients: The Network #9 Peritonitis Study. Am.J.Kidney Dis. 25:769-774:769-774, 1995. 70. Bunke, M., Brier, M.E., and Golper, T.A. Culture-negative CAPD peritonitis: the Network 9 Study. Adv.Perit.Dial. 10:174-178:174-178, 1994. 71. Burgess, E. Intraperitoneal cefoperazone treatment resulting in coagulation abnormality. Perit.Dial.Int. 10:180-181:180-181, 1990. 72. Buring, J.E., Evans, D.A., Mayrent, S.L., Rosner, B., Colton, T., and Hennekens, C.H. Randomized trials of aminoglycoside antibiotics: quantitative overview. Rev.Infect.Dis. 10:951-:951, 1988. 73. Burkart, J.M., Jordan, J.R., Durnell, T.A., and Case, L.D. Comparison of exit-site infections in disconnect versus nondisconnect systems for peritoneal dialysis. Perit.Dial.Int. 12:317-320:317-320, 1992. 74. Burke, J.F. Identification of the sources of staphylococci contaminating the surgical wound during operation. Ann.Surg. 82:788-:788, 1963. 75. Bush, A., Holt, J.E., Sankey, M.G., Kaye, C.M., and Gabriel, R. Penetration of metronidazole into continuous ambulatory peritoneal dialysate. Perit.Dial.Bull. 4:176-177:176-177, 1983. 76. Cairns, H.S., Beckett, J., Rudge, C.J., and et.al. Treatment of resistant CAPD peritonitis by temporary discontinuation of peritoneal dialysis. Clin.Nephrol. 32:27-30:27-30, 1989. 77. Calame, W., Hendrickx, R.J., Namavar, F., Oe, L.P., and Beelen, R.H. Effect of glucose in dialysis fluid on antibacterial defence in the peritoneal cavity. J.Infect. 30:227-233:227-233, 1995. 78. Cancarini, G.C., Manili, L., Brunori, G., Camerini, C., Zubani, R., Colombrita, D., Pezzola, D., and Maiorca, R. Simultaneous catheter replacement-removal during infectious complications in peritoneal dialysis. Adv.Perit.Dial. 10:210-213:210-213, 1994. 79. Cantaluppi, A., Graziani, G., Ponticelli, C., Grasso, S., Meinardi, G., Piaia, F., and Tamassia, V. Pharmacokinetic study of the new sulfamethopyrazine-trimethoprim combination (kelfiprim) in renal insufficiency. Eur.J.Clin.Pharmacol. 27:345-348:345-348, 1984. 80. Caramori, J.T., Barros, e.S.,M, Felipe, M.J., Sadatsune, T., Montelli, A.C., and Barretti, P. Successful treatment of fungal peritonitis in CAPD by intravenous, intraperitoneal, and intracatheter administration of amphotericin B. A case report [letter]. Perit.Dial.Int. 15:187-188:187-188, 1995. 81. Cecchin, E., De Marchi, S., Panarello, G., and Tesio, F. Chemotherapy and/or removal of the peritoneal catheter in the management of fungal peritonitis complicating CAPD. Nephron 40:251-252:251-252, 1985. 82. Centers for Disease Control Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee(HICPAC). M.M.W.R. 44:No.RR-12-:No.RR-12-, 1995. 83. Centers for Disease Control Nosocomial enterococci resistant to vancomycin. United States, 1989-1993. M.M.W.R. 42:597-599:597-599, 1993. 84. Chan, C.Y., Lai, K.N., Lam, A.W., and et.al. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continous ambulatory peritoneal dialysis. J.Antimicrob.Chemother. 27:225-232:225-232, 1991. 85. Chan, M.K., Cheng, I.K.P., and Ng, W.S. A randomised trial of three different regimens of treatment of peritonitis in patients on CAPD. Am.J.Kidney Dis. 15:155-159:155-159, 1990. 86. Chan, M.K., Chan, P.C.K., Cheng, I.P.K., Chan, C.Y., and Ng, W.S. Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment. Nephrol.Dial.Transplant. 4:814-817:814-817, 1989. 87. Chan, M.K., Chau, P.Y., and Chan, W.W.N. Oral treatment of peritonitis in CAPD patients with two dosage regimens of ofloxacin. J.Antimicrob.Chemother. 22:371-375:371-375, 1988. 88. Chan, M.K., Chau, P.Y., and Chan, W.W.N. Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Clin.Nephrol. 28:277-280:277-280, 1987. 89. Chan, M.K., Browning, A.K., Poole, C.J.M., Matheson, L.A., Li, C.S., Baillod, R.A., and Moorhead, J.F. Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis. Nephron 41:161-165:161-165, 1985. 90. Chan, T.M., Chan, C.Y., Cheng, S.W., Lo, W.K., Lo, C.Y., and Cheng, I.K. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients [see comments]. Nephrol.Dial.Transplant. 9:539-542:539-542, 1994. 91. Chapman, J.R. and Warnock, D.W. Ketoconazole and fungal CAPD peritonitis. Lancet 2:510-511:510-511, 1983. 92. Cheng, I.K., Chau, P.Y., Kumana, C.R., Chan, C.Y., Kou, M., and Siu, L.K. Single-dose pharmacokinetics of intraperitoneal ofloxacin in patients on continuous ambulatory peritoneal dialysis. Perit.Dial.Int. 13 Suppl 2:S383-5:S383-5, 1993. 93. Cheng, I.K., Chan, C.Y., Wong, W.T., Cheng, S.W., Ritchie, C.W., Cheung, W.C., and Lo, W.K. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit.Dial.Int. 13 Suppl 2:S351-4:S351-4, 1993. 94. Cheng, I.K.P., Chan, C.Y., Wong, W.T., Cheng, S.W., Ritchie, C.W., Cheung, W.C., and Lo, W.K. A randomized prospective comparison of oral vs intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit.Dial.Int. 13((suppl 2):S351-S354, 1992. 95. Cheng, I.K.P., Chan, C.Y., and Wong, W.T. A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin and aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis(CAPD). Perit.Dial.Int. 11:27-30:27-30, 1991. 96. Cheng, I.K.P., Chan, P.C., and Chan, M.K. Tuberculous peritonitis complicating long-term peritoneal dialysis. Report of 5 cases and review of the literature. Am.J.Nephrol. 9(2):155-161, 1989. 97. Cheng, I.K.P., Fang, G.X., Chan, T.M., Chan, P.C., and Chan, M.K. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Q.J.Med. 71:407-416:407-416, 1989. 98. Chesney, R.W. and Zelikovic, I. Peritonitis in childhood renal disease. Am.J.Nephrol. 8:147-160:147-160, 1988. 99. Chiou, Y.Y., Chen, W.P., Yang, L.Y., and Lin, C.Y. Peritonitis in children being treated with continuous ambulatory peritoneal dialysis. CAPD Team. Acta Paediatr.Sin. 36:176-183:176-183, 1995. 100. Chong, T.K., Piraino, B., and Bernardini, J. Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit.Dial.Int. 11:152-155:152-155, 1991. 101. Chow-tung, E., Lau, A., Vidyagar, D., and John, E.G. Effect of peritoneal dialysis on serum concentrations of 3 drugs commonly used in pediatric patients. Dev.Pharmacol.Ther. 8:85-95:85-95, 1985. 102. Churchill, D.N. Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients. Kidney Int. 43, Suppl.40:S-16-S-:S-16-S-22, 1993. 103. Churchill, D.N., Taylor, W., Cook, R.J., LaPlante, P., Barre, P., Cartier, P., Fay, W.P., Goldstein, M.B., Jindal, K., Mandin, H., McKenzie, J.K., Muirhead, N., Parfrey, P.S., Posen, G.A., Slaughter, D., Ulan, R.A., and Werb, R. Canadian hemodialysis morbidity study. Am.J.Kidney Dis. 19:214-234:214-234, 1992. 104. Churchill, D.N., Taylor, D.W., Vas, S.I., Oreopoulos, D.G., Bettcher, K.B., Fenton, S.S.A., Fine, A., Lavoie, S., Page, D., Wu, G., Beecroft, M.L., Pemberton, R., Wilczynski, N.L., deVeber, G.A., and Williams, W. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multicenter randomized clinical trial comparing the Y-connector disinfectant system to standard systems. Perit.Dial.Int. 9:159-163:159-163, 1989. 105. Churchill, D.N., Taylor, D.W., Vas, S.I., Singer, J., Beecroft, M.L., Wu, G., Manuel, A., Paton, T., Walker, S., Smith, E.K.M., and Oreopoulos, D.G. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients: a randomized clinical trial of co-trimoxazole prophylaxis. Perit.Dial.Intl. 8:125-138:125-138, 1988. 106. Clark, E.C., Silver, S.M., Hollick, G.E., and Rinaldi, M.G. Continuous ambulatory peritoneal dialysis complicated by Aureobasidium pullulans peritonitis. Am.J.Nephrol. 15:353-355:353-355, 1995. 107. Clayman, M.D., Raymond, A., Colen, D., Moffit, C., Wolf, C., and Neilson, E. The Limulus amebocyte lysate assay. Arch.Intern.Med. 147:337-340:337-340, 1987. 108. Cohen, L. and Bailey, D. Efficacy of intraperitoneal clindamycin in refractory peritonitis - report of two cases. Perit.Dial.Bull. 4:92-94:92-94, 1984. 109. Coles, G.A. and for the Mupirocin Study Group The effect of intranasal mupirocin on CAPD exit site infection. J.Am.Soc.Nephrol. 5:439-:439, 1994. 110. Coles, G.A., Minors, S.J., Horton, J.K., Fifield, R., and Davies, M. Can the risk of peritonitis be predicted for new continuous ambulatory peritoneal (CAPD) patients? Perit.Dial.Intl. 9:69-72:69-72, 1989. 111. Costerton, J.W., Ellis, B., Lam, K., Johnson, F., and Khoury, A.E. Mechanism of electrical enhancement of efficacy of antibiotics in killing biofilm bacteria. Antimicrob.Agents Chemother. 38(12):2803-2809, 1994. 112. Costerton, J.W., Khoury, A.E., Ward, K.H., and Anwar, H. Practical measures to control device-related bacterial infections. Int.J.Artif.Organs 16(11):765-770, 1993. 113. Dalac, S., Kazmierczak, A., Cabanne, J.F., Pechinot, A., Duez, J.M., Tanter, Y., and Rifle, G. Blood and peritoneal dialysate (PD) levels of cefoperazone (CFP) in patients on continuous ambulatory peritoneal dialysis (CAPD). Proceedings.of.the.22nd.Interscience.Conference.on.Antimicrobial.Agents and.Chem. 87-87-87, 1982. 114. Darouiche, R.O., Dhir, A., Miller, A.J., and et.al. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J.Infect.Dis. 170:720-723:720-723, 1994. 115. Dasgupta, M.K., Tyrrell, D.L.J., Costerton, J.W., and et.al. Detection of sessile biofilm bacteria in culture negative CAPD associated peritonitis. Adv.Perit.Dial. 11:157-162:157-162, 1995. 116. Dasgupta, M.K. Silver peritoneal catheters reduce bacterial colonization. Adv.Perit.Dial. 10:195-198:195-198, 1994. 117. Dasgupta, M.K., Bettcher, K.B., Ulan, R.A., Burns, V., Lam, K., Dossetor, J.B., and Costerton, J.W. Relationship of adherent bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis. Perit.Dial.Bull. 7:168-173:168-173, 1987. 118. Davies, S.J., Ogg, C.S., Cameron, J.S., Poston, S., and Noble, W.C. Staphylococcus aureus nasal carriage exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Perit.Dial.Int. 9:61-64:61-64, 1989. 119. Davies, S.J., Wessels, D.J., Gibson, J., Pattison, J., and Turney, J.H. Successful oral treatment of candida peritonitis. Perit.Dial.Bull. 5:257-258:257-258, 1985. 120. Davis, G.M., Forland, S.C., and Cutler, R.E. Serum and dialysate concentrations of cephalexin following repeated dosing in CAPD patients. Am.J.Kidney Dis. 6:177-180:177-180, 1985. 121. de Fijter, C.W., Verbrugh, H.A., Oe, P.L., Heezius, E.C., Verhoef, J., and Donker, A.J. Antibacterial peritoneal defence in automated peritoneal dialysis: advantages of tidal over continuous cyclic peritoneal dialysis? Nephrol.Dial.Transplant. 9:156-162:156-162, 1994. 122. de Fijter, C.W., Biemond, A., Oe, L.P., and et.al. Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. Adv.Perit.Dial. 8:18-21:18-21, 1992. 123. De Saedeleer, B., Sennesael, J., Van der Niepen, P., and Verbeelen, D. Intraperitoneal fluconazole therapy for Trichosporon cutaneum peritonitis in continuous ambulatory peritoneal dialysis. Nephrol.Dial.Transplant. 9:1658-1659:1658-1659, 1994. 124. De Vecchi, A.F. Imipenem/cilastatin in the treatment of CAPD peritonitis [letter; comment]. Am.J.Nephrol. 15:180-180:180, 1995. 125. Debruyne, D. and Rycklynck, J.P. Clinical pharmacokinetics of fluconazole. Clin.Pharmacokinet. 24:10-27:10-27, 1993. 126. Demotes-Mainard, F., Vincon, G., Ragnaud, J.M., and et.al. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in continous ambulatory peritoneal dialysis. J.Clin.Pharmacol. 33:475-479:475-479, 1993. 127. Denis, F., Mounier, M., Lagarde, C.H., and Benevent, D. Treatment de peritontes des insuffisants remaux en dialyse peritoneal continue ambulatoire par la pefloxacine. Pathol.Biol. 35:652-655:652-655, 1987. 128. Dharmasena, D., Roberts, D.E., Coles, G.A., and Williams, J.D. Pharmacokinetics of IP ciprofloxacin in patients on CAPD. J.Antimicrob.Chemother. 23:253-259:253-259, 1989. 129. Dimkovic, N.B., Dakie, G.D., Radovanovic, L.T., and Jovanovic, D.R. Preliminary experience with a vaccination against Staphylococcus epidermidis in patients on chronic peritoneal dialysis. Perit.Dial.Int. 13:315-317:315-317, 1993. 130. Doebbeling, B.N. Nasal and hand carriage of Staphylococcus aureus in healthcare workers. J.Chemother. 6:11-17:11-17, 1994. 131. Domrongkitchaiporn, S., Karim, M., Watson, L., and Moriarty, M. The influence of continuous ambulatory peritoneal dialysis connection technique on peritonitis rate and technique survival. Am.J.Kidney Dis. 24:50-58:50-58, 1994. 132. Dratwa, M., Glupczynski, Y., Lameire, N., Matthys, D., Verschraegen, G., Vaneechoutte, M., Boelaert, J., Schurgers, M., Van Landuyt, H., Verbeelen, D., and et.al. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev.Infect.Dis. 13(suppl 7):S645-S647, 1991. 133. Dratwa, M., Glupczynski, Y., Lameire, N., Verschraegen, G., Boelaert, J., Van Landuyt, H., Verbeelen, D., and Lauwers, S. Treatment of gram negative (G-) peritonitis (P) in CAPD patients (Pts) with aztreonam (AZT). Perit.Dial.Bull. 7:S25-S25:S25, 1987. 134. Drew, P.J.T., Casewell, M.W., Desai, N., Houang, E.T., Simpson, C.N., and Marsch, F.P. Cephalexin for the oral treatment of CAPD peritonitis. J.Antimicrob.Chemother. 13:153-159:153-159, 1984. 135. Dryden, M. and Eykyn, S.J. Short-course gentamicin in gram-negative CAPD peritonitis [letter]. Lancet 341:497-497:497, 1993. 136. Dryden, M.S., Wing, A.J., and Phillips, L. Low dose IP ciprofloxacin for the treatment of peritonitis in patients receiving CAPD. J.Antimicrob.Chemother. 28:131-139:131-139, 1991. 137. Edmond, M.B., Wenzel, R.P., and Pascule, A.W. Vancomycin resistant Staphylococcus aureus: Prespectives on measures needed for control. Ann.Intern.Med. 124:329-334:329-334, 1996. 138. Eisele, G. and Bailie, G.R. Successful treatment of Aeromonas hydrophila peritoneal dialysis-associated peritonitis using intermittent intraperitoneal gentamicin. Clin.Nephrol. 44(6):402, 1995. 139. Eisele, G., Adewunni, C., Bailie, G.R., Yocum, D., and Venezia, R. Surreptitious use of antimicrobial agents by CAPD patients. Perit.Dial.Int. 13:313-315:313-315, 1993. 140. Eisenberg, E.S. Intraperitoneal flucytosine in the management of fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Am.J.Kidney Dis. 11:465-467:465-467, 1988. 141. Eklund, B.H., Hankanen, E.O., Kala, A., and Kyllönen, L.E. Catheter configuration and outcome in patients on continuous ambulatory peritoneal dialysis: a prospective comparison of two catheters. Perit.Dial.Int. 14:70-74:70-74, 1996. 142. Elliott, G.R., Peterson, P.K., and Verbrugh, H.A. Influence of subinhibitory concentrations of clindamycin on staphylococcus aureus growth in human phagocytic cells. Antimicrob.Agents Chemother. 22:781-784:781-784, 1982. 143. Fabris, A., Pellanda, M.V., Gardin, C., Contestabile, A., and Bolzonella, R. Pharmacokinetics of antifungal agents. Perit.Dial.Int. 13 Suppl 2:S380-2:S380-2, 1993. 144. Fabris, A., Biasioli, S., Borin, D., Brendolan, A., Chiaramonte, S., Feriani, M., Pisani, E., Ronco, C., and LaGreca, G. Fungal peritonitis in peritoneal dialysis: Our experience and review of treatments. Perit.Dial.Bull. 4:75-77:75-77, 1984. 145. Fang, G.X., Lo, W.K., Chan, T.M., and et.al. A randomised prospective comparison of oral vs IP ofloxacin as primary treatment of bacterial peritonitis complicating CAPD. Abstracts.6th.Asian.Pacific.Congress.of.Nephrology. 126-, 1995. 146. Farber, B.F., Kaplan, M.H., and Glogston, A.G. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J.Infect.Dis. 161:37-40:37-40, 1990. 147. Farias, M.G., Soucie, J.M., McClellan, W., and Mitch, W.E. Race and the risk of peritonitis: an analysis of factors associated with the initial episode. Kidney Int. 46:1392-1396:1392-1396, 1994. 148. Favre, H. and Probst, P. Pharmacokinetics of ceftriaxone after intravenous administration to CAPD patients with and without peritonitis. Chemioterapia. (Suppl 2):273-274, 1987. 149. Fein, P., Hurtado, H., Jorden, A., and Avram, M.M. New modified schedule for antibiotic delivery in CAPD. Kidney Int. 29:231-231:231, 1986. 150. Fein, P.A., Hurtado, H., Jorden, A., and Avram, M.M. A new, simplified antibiotic regimen for treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Perit.Dial.Bull. 6:S6-S6:S6, 1986. 151. Fellin, G., Gentile, M.G., Guerra, L., and et.al. Exit-site infection: a randomized trial on topical vs parenteral therapy. Adv.in CAPD. 4:169-171:169-171, 1988. 152. Fellin, G., Gentile, M.G., and Manna, G.M. Peritonitis prevention: Y connector and sodium hypochlorite. Three years' experience. Report of the Italian Study Group. Perit.Dial.Int,.Inc.Toronto. 114-118-118, 1987. 153. Fenton, P. Laboratory diagnosis in patients undergoing continuous ambulatory peritoneal dialysis. J.Clin.Path. 35:1181-1184:1181-1184, 1982. 154. Findon, G. and Miller, T. Bacterial peritonitis in continuous ambulatory peritoneal dialysis: effect on dialysis on host defense mechanisms. Am.J.Kidney Dis. 26:765-773:765-773, 1995. 155. Fine, A., Cox, D., and Bouw, M. Higher incidence of peritonitis in native Canadians on continuous ambulatory peritoneal dialysis. Perit.Dial.Int. 14:227-230:227-230, 1994. 156. Fine, R.N., Salusky, I.B., Hall, T., Lucullo, L., Jordan, S.C., and Ettenger, R.B. Peritonitis in children undergoing continuous ambulatory peritoneal dialysis. Pediatrics 71:806-809:806-809, 1983. 157. Fivush, B.A., Case, B., May, M.W., and Lederman, H.M. Hypogammaglobulinemeia in children undergoing continuous ambulatory peritoneal dialysis. Pediatr.Nephrol. 3:186-188:186-188, 1989. 158. Flanigan, M.J., Hochstetler, L.A., Langholdt, D., and Lim, V.S. Continuous ambulatory peritoneal dialysis catheter infections: Diagnosis and management. Perit.Dial.Int. 14:248-254:248-254, 1994. 159. Fleming, L.W., Phillips, G., Stewart, W.K., and Scott, A.C. Oral ciprofloxacin in the treatment of peritonitis in patients on CAPD. J.Antimicrob.Chemother. 25:441-448:441-448, 1990. 160. Fleming, L.W., Phillips, G., Moreland, T.A., Stewart, W.K., and Scott, A.C. Oral ciprofloxacin for the treatment of peritonitis in patients on CAPD. Rev.Infect.Dis. 11((suppl 5):S1294-S1296, 1989. 161. Fleming, L.W., Moreland, T.A., Scott, A.C., Stewart, W.K., and White, L.O. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. J.Antimicrob.Chemother. 19:493-503:493-503, 1987. 162. Flor, S., Guay, D., Opsahl, J.A., Tack, K., and Matzke, G. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment. Int.J.Clin.Pharmacol.Res. 11:115-121:115-121, 1991. 163. Friedland, J.S., Iveson, T.J., Fraise, A.P., Winearls, C.G., Selkon, J.B., and Oliver, D.O. A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). J.Antimicrob.Chemother. 26((suppl F):77-81, 1990. 164. Friedlander, M. Peritoneal function and peritonitis in patients on peritoneal dialysis [editorial; comment]. J.Lab.Clin.Med. 122:639-640:639-640, 1993. 165. Frongillo, R.F., Donati, L., Federico, G., Martino, P., Moroni, M., Ortona, L., Palumbo, M., Pasticci, B.M., Pizzigallo, E., Privitera, G., Serra, P., Signorini, M., Venditti, M., and Pauluzzi, S. Clinical comparative study on the activity of cefamandole in the treatment of serious staphylococcal infections caused by methicillin-susceptible and methicillin-reistant strains. Antimicrob.Agents Chemother. 29:789-796:789-796, 1986. 166. Gagnon, R.F., Richards, G.K., and Kostiner, G.B. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv.Perit.Dial. 10:189-192:189-192, 1994. 167. Gagnon, R.F., Shuster, J., and Kaye, M. Auto-immunity in patients with end-stage renal disease maintained on hemodialysis and continuous ambulatory peritoneal dialysis. J.Clin.Lab.Immunol. 11:155-158:155-158, 1983. 168. Galato, R., Seveso, M., Urso, R., Bartucci, F., and Sassella, D. Pharmacokinetics of intraperitoneal cefotaxime in CAPD patients. Perit.Dial.Bull. 7:S32-S32:S32, 1987. 169. Ganga, U.R. and Schafer, L. Tuberculous peritonitis: a case report and literature review. S.D.J.Med. 45(10):287-289, 1992. 170. Gendeh, B.S., Said, H., Gibb, A.G., Aziz, N.S., Kong, N., and Zahir, Z.M. Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis. J.Laryngol.Otol. 107:681-685:681-685, 1993. 171. Gendeh, B.S., Said, H., Gibb, A.G., and et.al. Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis. J.Laryngol.Otol. 105:999-1001:999-1001, 1991. 172. Gerig, J.S., Bolton, N.D., Swabb, E.A., Scheld, W.M., and Bolton, W.K. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int. 26:308-318:308-318, 1984. 173. Giladi, M., Lee, B.E., Berlin, O.G., and Panosian, C.B. Peritonitis caused by mycobacterium kansasii in a patient undergoing continuous ambulatory peritoneal dialysis. Am.J.Kidney Dis. 19(6):597-599, 1992. 174. Gilbert, A.I. and Felton, L.L. Infection in inguinal hernia repair considering biomaterials and antibiotics[published erratum appears in Surg Gynecol Obstet 1993 Nov;177(5):528]. Surg.Gynecol.Obstet. 177(2):126-130, 1993. 175. Gilbert, D.N. Once-daily aminoglycoside therapy. Antimicrob.Agents Chemother. 35:399-405:399-405, 1991. 176. Glancey, G.R., Cameron, J.S., and Ogg, C.S. Peritoneal drainage: an important element in host defense against staphylococcal peritonitis in patients on CAPD. Nephrol.Dial.Transplant. 7:627-631:627-631, 1992. 177. Glasson, P. and Favre, H. Treatment of peritonitis in continuous ambulatory peritoneal dialysis patients with co-trimoxazole. Nephron 36:65-67:65-67, 1984. 178. Gokal, R., Mistry, C.D., and Peers, E.M. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Perit.Dial.Int. 15:226-230:226-230, 1995. 179. Gokal, R., Ash, S.R., Helfrich, G.B., Holmes, C.J., Joffe, P., Nichols, W.K., Oreopoulos, D.G., Riella, M.C., Slingeneyer, A., Twardowski, Z.J., and Vas, S.I. Peritoneal catheters and exit-site practices: Toward optimum peritoneal access. Perit.Dial.Int. 13:29-39:29-39, 1993. 180. Gokal, R. Continuous ambulatory peritoneal dialysis. Kluwer.Academic.Publishers,.Dordrecht,Netherlands. Third:590-615:590-615, 1989. 181. Gokal, R. World wide experience, cost effectiveness. Churchill.Livingstone,.Edinburgh. 349-369-369, 1986. 182. Golper, T.A., Hartstein, A.I., Morthland, V.H., and Christensen, J.M. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 31:1787-1790:1787-1790, 1987. 183. Golper, T.A. and Hartstein, A.I. Analysis of the causative pathogens in uncomplicated CAPD-associated peritonitis: Duration of therapy, relapses, and prognosis. Am.J.Kidney Dis. 7(2):141-145, 1986. 184. Golper, T.A., Sewell, D.L., Fisher, P.B., and Wolfson, M. Incomplete activation of intraperitoneal clindamycin phosphate during peritoneal dialysis. Am.J.Nephrol. 4:38-42:38-42, 1984. 185. Golper, T.A. Drugs and peritoneal dialysis. Dialysis.and.Transplantation 8:41-43:41-43, 1979. 186. Golper, T.A., Bennett, W.M., and Jones, S.R. Peritonitis associated with chronic peritoneal dialysis: a diagnostic and therapeutic approach. Dialysis.and.Transplantation 7:1173-1178:1173-1178, 1978. 187. Gonthier, D., Bernardini, J., Holley, J.L., and Piraino, B. Erythema: does it indicate infection in a peritoneal catheter exite site? Adv.Perit.Dial. 8:230-233:230-233, 1992. 188. Govaerts, P.J., Claes, J., Van De Heyning, P.H., Jorens, P.G., Marquet, J., and De Broe, M.E. Aminoglycoside-induced ototoxicity. Toxicol.Lett. 52:227-251:227-251, 1990. 189. Grant, A.C., Lacey, R.W., Brownjohn, A.M., and Turney, J.H. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet ii:1166-1167:1166-1167, 1986. 190. Grave, W. and Sturm, A.W. Treatment of pseudomonas aeroginosa peritonitis in a CAPD peritonitis with ciprofloxacin. Nephrol.Dial.Transplant. 3:707-:707, 1988. 191. Gray, H.H., Goulding, S., and Eykyn, S.J. Intraperitoneal vancomycin and ceftazidime in the treatment of CAPD peritonitis. Clin.Nephrol. 23:81-84:81-84, 1985. 192. Greaves, W.L., Kreeft, J.H., Ogilvie, R.I., and Richards, G.K. Cefoxitin disposition during peritoneal dialysis. Antimicrob.Agents Chemother. 19:253-255:253-255, 1981. 193. Gristina, A.G., Giridhar, G., Gabriel, B.L., Naylor, P.T., and Myrvik, Q.N. Cell biology and molecular mechanisms in artificial device infections. Int.J.Artif.Organs 16(11):755-763, 1993. 194. Gross, M.L., Somani, P., Ribner, B.S., Raeader, R., Freimer, E.H., and Higgins, J.T. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 34:673-680:673-680, 1983. 195. Gruer, L.D., Turney, J.H., Curley, J., Michael, J., and Adu, D. Vancomycin and tobramycin in the treatment of CAPD peritonitis. Nephron 41:279-282:279-282, 1985. 196. Gruer, L.D., Kiddy, K., Adu, D., and Michael, J. Once-daily antibiotic treatment of CAPD peritonitis. Lancet ii:1282-1283:1282-1283, 1984. 197. Grynoch, R., Ulan, R., Harley, K., Bettcher, V., Burns, K., Kowaleska, C., Gratton, C., Grace, M., and Wenman, W. Ticarcillin-clavulanic acid for the treatment of CAPD peritonitis. Perit.Dial.Bull. 7:S38-S38:S38, 1987. 198. Guay, D.R.P., Awni, W.M., Halstenson, C.E., Kenny, M.T., Keane, W.F., and Matzke, G.R. Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing. Antimicrob.Agents Chemother. 33:2012-2015:2012-2015, 1989. 199. Guay, D.R.P., Awni, W.M., Fant, B., Kenny, M., and Matzke, G.R. Pharmacokinetics (PK) of teicoplanin (T) in continuous ambulatory peritoneal dialysis (CAPD) patients. Proceedings.of.the.28th.Interscience.Conference.on.Antimicrobial.Agents and.Chem. 134-134-134, 1988. 200. Guay, D.R.P., Matzke, G.R., Heim, K.L., Halstenson, C.E., Abraham, P.A., and Keane, W.F. Influence of gender on the disposition of cefotaxime and desacetylcefotaxime in patients with end stage renal disease. Ther.Drug Monit. 9:259-262:259-262, 1987. 201. Guay, D.R.P., Klicker, R., Pence, T., and Peterson, P.K. In vitro antistaph activity of teicoplanin and ciprofloxacin in PD effluent. Eur.J.Clin.Microbiol. 5:661-663:661-663, 1986. 202. Guay, D.R.P., Meatherall, R.C., Harding, G.K., and Brown, G.R. Pharmacokinetics of cefixime (CL 284, 635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob.Agents Chemother. 30:485-490:485-490, 1986. 203. Guay, D.R.P., Meatherall, R.C., Baxter, H., Jacyk, W.R., and Penner, B. Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 25:306-310:306-310, 1984. 204. Gucek, A., Bren, A.F., Lindic, J., Hergouth, V., and Mlinsek, D. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients? Adv.Perit.Dial. 10:144-146:144-146, 1994. 205. Gutfeld, M.B., Reddy, P.V., and Morse, G.D. Vancomycin-associated exfoliated dermatitis during continuous ambulatory peritoneal dialysis. Drug Intell.Clin.Pharmacol. 22:881-882:881-882, 1988. 206. Halstenson, C.E., Wong, M.O., Johnson, C.A., and et.al. Pharmacokinetics of tazobactam MI metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J.Clin.Pharmacol. 34:1208-1217:1208-1217, 1994. 207. Halstenson, C.E., Blevins, R.B., Salem, N.G., and Matzke, G.R. Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. Clin.Nephrol. 22:239-243:239-243, 1984. 208. Hancock, K. and Hulme, B. Treatment of CAPD peritonitis with oral ciprofloxacin. Nephrol.Dial.Transplant. 4:759-:759, 1989. 209. Harford, A.M., Sica, D.A., Tartaglione, T., Polk, R.E., Dalton, H.P., and Poynor, W. Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis. Nephron 43:217-222:217-222, 1986. 210. Hart, P.H., Jones, C.A., and Finlay-Jones, J.J. Inflammatory fluids regulate TNF-alpha, but not IL-1 beta, production by human peritoneal macrophages. A study of patients on continuous ambulatory peritoneal dialysis with peritonitis. J.Leukoc.Biol. 53:309-319:309-319, 1993. 211. Hasbargen, B.J., Rodgers, D.J., Hasbargen, J.A., Quinn, M.J., and James, M.K. Exit-site care--is it time for a change? Perit.Dial.Int. 13((suppl 2):S313-S315, 1993. 212. Heghesan, H. Rhodotorula peritonitis in continuous ambulatory peritoneal dialysis. Perit.Dial.Bull. 216-217-217, 1983. 213. Heim, K.L., Halstenson, C.E., Comty, C.M., Affrime, M.B., and Matzke, G.R. Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 30:15-19:15-19, 1986. 214. Hodler, J.E., Galeazzi, R.L., Rudhardt, M., and Seiler, A.J. Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications. Eur.J.Clin.Pharmacol. 26:609-612:609-612, 1984. 215. Holley, H.P., Tucker, C.T., Moffatt, T.L., Dodds, K.A., and Dodds, H.M. Tuberculosis peritonitis in patients undergoing chronic home peritoneal dialysis. Am.J.Kidney Dis. 1:222-226:222-226, 1982. 216. Holley, J.L., Bernardini, J., and Piraino, B. Infecting organisms in continuous ambulatory peritoneal dialysis patients on the Y-set. Am.J.Kidney Dis. 23:569-573:569-573, 1994. 217. Holley, J.L., Bernardini, J., and Piraino, B. A comparison of peritoneal dialysis-related infections in black and white patients. Perit.Dial.Int. 13:45-49:45-49, 1993. 218. Holley, J.L. and Moss, A.H. A prospective evaluation of blood culture versus standard plate techniques for diagnosing peritonitis in continuous ambulatory peritoneal dialysis. Am.J.Kidney Dis. 13:184-188:184-188, 1989. 219. Honkanen, E., Von Bonsdorf, M., and Hortling, L. Rhodotorula peritonitis in continuous ambulatory peritoneal dialysis. Perit.Dial.Bull. 3:216-217:216-217, 1983. 220. Huang, T.C. and Chung, W.K. Fluconazole in the treatment of candida peritonitis in continuous ambulatory peritoneal dialysis: report of a case. J.Formos.Med.Assoc. 92:190-191:190-191, 1993. 221. Huang, T.P. and Lin, C.Y. Intraperitoneal recombinant human erythropoietin therapy: influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis. Am.J.Nephrol. 15:312-317:312-317, 1995. 222. Innes, A., Burden, R.P., Finch, R.G., and Morgan, A.G. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial. Nephrol.Dial.Transplant. 9:797-799:797-799, 1994. 223. Janicke, D.M., Morse, G.D., Apicella, M.A., Jusko, W.J., and Walshe, J.J. Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin.Pharmacol.Ther. 40:209-218:209-218, 1986. 224. Janknegt, R. CAPD peritonitis and flouroquinolones: a review. Perit.Dial.Int. 11:53-58:53-58, 1991. 225. Jansen, B. and Peters, G. Foreign body associated infection. J.Antimicrob.Chemother. 32(Suppl A):69-75, 1993. 226. Jindal, K.K. and Hirsch, D.J. Excellent technique survival on home peritoneal dialysis: Results of a regional program. Perit.Dial.Int. 14:324-326:324-326, 1994. 227. John, J.F. and McNeill, W.F. Activity of cephalosporins against methicillin-susceptible and methicillin-resistant, coagulase-negative staphylococci: minimal effect of beta-lactamase. Antimicrob.Agents Chemother. 17:179-183-179-183:179-183-179-183, 1980. 228. Johnson, C., Zimmerman, S., Leggett, J., Craig, W., Yeh, J., and Whall, T. Pharmacokinetics and pharmacodynamics of ampicillin (Amp)/sublactam (Sul) in CAPD patients. Proceedings.of.the.27th.Interscience.Conference.on.Antimicrobial.Agents and.Chem. 284-284-284, 1987. 229. Johnson, C.A., Ateshkadi, A., Zimmerman, S.W., Hughes, G.S., Craig, W.A., Carey, P.M., and Borin, M.T. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 37:2650-2655:2650-2655, 1993. 230. Johnson, C.A., Halstenson, C.E., Kelloway, J.S., and et.al. Single dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin.Pharmacol.Ther. 51:32-41:32-41, 1992. 231. Johnson, C.A., Zimmerman, S.W., Engeseth, S., and O'Brien, M. Intraperitoneal vancoled does not cause chemical peritonitis. Perit.Dial.Intl. 9:-, 1989. 232. Johnson, C.A., Zimmerman, S.W., Reitberg, D.P., Whall, T.J., Leggett, J.E., and Craig, W.A. Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 32:51-56:51-56, 1988. 233. Johnson, C.A., Welling, P.G., and Zimmerman, S.W. Pharmacokinetics of oral cephradine in continuous ambulatory peritoneal dialysis patients. Nephron 38:57-61:57-61, 1984. 234. Johnson, C.A., Zimmerman, S.W., and Rogge, M. The pharmacokinetics of antibiotics used to treat peritoneal dialysis-associated peritonitis. Am.J.Kidney Dis. 4:3-17:3-17, 1984. 235. Johnson, R.J., Blair, A.D., and Ahmad, S. Ketoconazole kinetics in chronic peritoneal dialysis. Clin.Pharmacol.Ther. 37:325-329:325-329, 1985. 236. Johnson, R.J., Ramsey, P.G., Gallagher, N., and Ahmad, S. Fungal peritonitis inpatientts on peritoneal dialysis: incidence, clinical features and prognosis. Am.J.Nephrol. 5:169-175:169-175, 1985. 237. Jones, J.M. and Greenfield, R.A. Administration of flucytosine to a patient on CAPD. Perit.Dial.Bull. 2:46-46:46, 1982. 238. Jones, T.E., Milne, R.W., Mudaliar, Y., and Sansom, L.N. Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration. Antimicrob.Agents Chemother. 28:293-298:293-298, 1985. 239. Jung, K., Brauner, A., Kuhn, I., Ransjo, U., Hylander, B., Flock, J.I., and Mollby, R. Typing of coagulase-negative staphylococci from peritonitis in CAPD-patients by the PhP-CS system and REA. APMIS 103:679-685:679-685, 1995. 240. Kalya, A.V. and Ahearn, D.G. Increased resistance to antifungal antibiotics of Candida spp. adhered to silicone. J.Ind.Microbiol. 15(6):451-455, 1995. 241. Kampf, D., Borner, K., Hain, H., and Conrad, W. Multiple dose kinetics of ofloxacin after intraperitoneal application in CAPD patients. Perit.Dial.Int. 11:317-321:317-321, 1991. 242. Kant, K.S., Goetz, D., Marzluff, C., and Motz, D. Relapsing peritonitis in continuous ambulatory peritoneal dialysis (CAPD): treatment by interruption of CAPD and prolonged antibiotic therapy. Perit.Dial.Intl. 8:155-157:155-157, 1988. 243. Kazmi, H.R., Raffone, F.D., Kliger, A.S., and Finkelstein, F.O. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. J.Am.Soc.Nephrol. 2:1498-1501:1498-1501, 1992. 244. Keane, W.F. and Vas, S.I. Peritonitis. Kluwer,.Amsterdam. 473-501-501, 1994. 245. Keane, W.F., Everett, E.D., Golper, T.A., Gokal, R., Halstenson, C., Kawaguchi, Y., Riella, M., Vas, S., and Verbrugh, H.A. Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis. Perit.Dial.Int. 13:14-28:14-28, 1993. 246. Keane, W.F., Everett, E.D., Fine, R.N., Golper, T.A., Vas, S., Peterson, P.K., Gokal, R., and Matzke, G.R. Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update. Perit.Dial.Int. 9:247-256:247-256, 1989. 247. Keane, W.F., Bergerson, B., Pence, T., and Peterson, P.K. Challenges for continuous ambulatory peritoneal dialysis. Bailliere.Tindall.Publishers,.London. 1255-1267-1267, 1988. 248. Keane, W.F., Everett, E.D., Fine, R.N., Golper, T.A., Vas, S.I., and Peterson, P.K. CAPD related peritonitis management and antibiotic therapy recommendations. Perit.Dial.Bull. 7:55-68:55-68, 1987. 249. Keane, W.F., Comty, C.M., Verbrugh, H.A., and Peterson, P.K. Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. Kidney Int. 25:539-543:539-543, 1984. 250. Keane, W.F. and Peterson, P.K. Host defense mechanisms of the peritoneal cavity and continuous ambulatory peritoneal dialysis. Perit.Dial.Bull. 4:122-127:122-127, 1984. 251. Keane, W.F., Comty, C.M., and Peterson, P.K. Opsonic deficiency of the peritoneal cavity: a risk factor for peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int. 25:539-543:539-543, 1984. 252. Keane, W.F. and Peterson, P.K. Peritonitis during continuous ambulatory peritoneal dialysis: the role of host defense mechanisms. Trans.Am.Soc.Artif.Intern.Organs XXX:684-686:684-686, 1984. 253. Keller, E. Pharmacokinetics and pharmacodynamics of antistaphylococcal antibiotics in continuous ambulatory peritoneal dialysis patients. Perit.Dial.Int. 13 Suppl 2:S367-70:S367-70, 1993. 254. Keller, E. Peritoneal kinetics of different drugs. Clin.Nephrol. 30:S24-S28:S24-S28, 1988. 255. Keller, E., Jansen, A., Pelz, K., Hoppe-Seyler, G., and Schollmeyer, P. Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 35:208-213:208-213, 1984. 256. Keogh, J.A.B., Carr, M.E., Murray, F., McEvoy, M., Grant, G., and Keane, C.T. Treatment of fungal peritonitis in CAPD patients using peritoneal lavage. Perit.Dial.Bull. 5:67-69:67-69, 1985. 257. Kerr, C.M., Perfect, J.R., Craven, P.C., Jorgensen, J.H., Drutz, D.J., Shelburne, J.D., Gallis, H.A., and Gutman, R.A. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann.Intern.Med. 99:334-337:334-337, 1983. 258. Ketyi, I. Effectiveness of antibiotics on the autochthonous Escherichia coli of mice in the intestinal biofilm versus its planktonic phase. Acta Microbiol.Immunol.Hung. 41(2):189-195, 1994. 259. Khanna, R., Nolph, K.D., Prowant, B.F., and Twardowski, Z.J. Computer interaction: peritonitis. Adv.Perit.Dial. 10:19-21:19-21, 1994. 260. Kiefer, T., Schenk, U., Weber, J., and et.al. Incidence and significance of pneumoperitoneum in continuous ambulatory peritoneal dialysis. Am.J.Kidney Dis. 22:30-35:30-35, 1993. 261. Kiernan, L., Kliger, A., Gorban-Brennan, N., Juergensen, P., Tesin, D., Vonesh, E., and Finkelstein, F. Comparison of continuous ambulatory peritoneal dialysis-related infections with different Y-tubing exchange systems. J.Am.Soc.Nephrol. 5:1835-1838:1835-1838, 1995. 262. Kimmel, P.L., Umana, W.O., Simmens, S.J., Watson, J., and Bosch, J.P. Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease. Kidney Int. 44:373-378:373-378, 1993. 263. Kirmani, N., Tuazon, C.U., Murray, H.W., Parrish, A.E., and Sheagren, J.N. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch.Intern.Med. 138:1657-1659:1657-1659, 1978. 264. Klaus, G., Schaefer, F., Muller-wiefel, D., Mehls, O., and Members of the Arbeitgemeinschaft Paediatrische Nephrologie Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Adv.Perit.Dial. 11:298-301:298-301, 1995. 265. Klaus, G., Schafer, F., Querfeld, U., Soergel, M., Wolf, S., and Mehls, O. Treatment of relapsing peritonitis in pediatric patients on peritoneal dialysis. Adv.Perit.Dial. 8:302-305:302-305, 1992. 266. Knight, K.R. and Polak, A. Laboratory diagnosis and oral treatment of CAPD peritonitis. Lancet ii:1301-1304:1301-1304, 1982. 267. Korbet, S.M., Vonesh, E.F., and Firanek, C.A. A retrospective assessment of risk factors for peritonitis among an urban CAPD population. Perit.Dial.Int. 13:126-131:126-131, 1993. 268. Korzets, Z., Maayan, M.C., and Bernheim, J. Flavobacterial peritonitis in patients treated by peritoneal dialysis. Nephrol.Dial.Transplant. 10:280-283:280-283, 1995. 269. Koup, J.R., Keller, E., Neumann, H., and Stoeckel, K. Ceftriaxone pharmacokinetics during peritoneal dialysis. Eur.J.Clin.Pharmacol. 30:303-307:303-307, 1986. 270. Kovarik, J.M., Guay, D.R.P., Gekker, G., Keane, W.F., and Peterson, P.K. Uptake and activity of teicoplanin against S. epidermidis in human peritoneal ma. Proceedings.of.the.26th.Interscience.Conference.on.Antimicrobial.Agents and.Chem. 323-323-323, 1986. 271. Kowalsky, S., Echols, R., McCormick, E., and Andrews, E. Pharmacokinetics of ciprofloxacin (CIP) in subjects with varying degrees of renal function and on hemodialysis (HD). Proceedings.of.the.25th.Interscience.Conference.on.Antimicrobial.Agents and.Chem. 278-278-278, 1985. 272. Kowalsky, S.F., Echols, M., Schwartz, M.T., Bailie, G.R., and McCormick, E. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Clin.Nephrol. 39:53-58:53-58, 1993. 273. Krediet, R.T., Boeschoten, E.W., Struijk, D.G., and Arisz, L. Pharmacokinetics of intraperitoneally (IP) administered 5-fluorocytosine (5-FC) in CAPD patients. Perit.Dial.Bull. 7:S43-S43:S43, 1987. 274. Krediet, R.T., Zuyderhoudt, F.M., Boeschoten, E.W., and Arisz, L. Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur.J.Clin.Invest. 17(1):43-52, 1987. 275. Krothapalli, R., Duffy, W.B., Lacke, C., Payne, W., Patel, H., Perez, V., and Senekjian, H.O. Pseudomonas peritonitis and continuous ambulatory peritoneal dialysis. Arch.Intern.Med. 142:1862-1863:1862-1863, 1982. 276. Krothapalli, R.K., Senekjian, H.O., and Ayus, J.C. Efficacy of intravenous vancomycin in the treatment of Gram-positive peritonitis in long-term peritoneal dialysis. Am.J.Med. 75:345-348:345-348, 1983. 277. Kuizon, B., Melocoton, T.L., Holloway, M., Ingles, S., Jing, H.E., Fonkalsrud, E.W., and Salusky, I.B. Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution. Pediatr.Nephrol. 9:S12-S17:S12-S17, 1995. 278. Lameire, N. and Belpaire, F. Pharmacokinetics of antibiotics against gram-negative infections in continuous ambulatory peritoneal dialysis patients. Perit.Dial.Int. 13(Suppl 2):S371-S376, 1993. 279. Lameire, N., Rosenkranz, B., Malerczyk, V., Lehr, K.H., Veys, N., and Ringoir, S. Ofloxacin pharmacokinetics in chronic renal failure and dialysis. Clin.Pharmacokinet. 21:357-371:357-371, 1991. 280. Lameire, N., Matthys, D., Bogaert, A.M., Belpaire, F., and Bogaert, M. Pharmacokinetics of netilmicin after intravenous (IV) and intraperitoneal (IP) administration in CAPD. Perit.Dial.Bull. 7:S45-S45:S45, 1987. 281. Lamperi, S. and Carozzi, S. Defective opsonic activity of peritoneal effluent during continuous ambulatory peritoneal dialysis (CAPD): Importance and prevention. Perit.Dial.Bull. 6:87-92:87-92, 1986. 282. Lamperi, S. and Carozzi, S. Suppressor resident peritoneal macrophages and peritonitis incidence in continuous ambulatory peritoneal dialysis. Nephron 44:219-225:219-225, 1986. 283. Leclerco, R., Derlot, E., Duval, J., and Courvalin, P. Plasmid-mediated resistance to vancomycin and teicoplanin in enterococcus faecium. N.Engl.J.Med. 319:157-161:157-161, 1988. 284. Lee, S., Chiang, S., Hseih, S., and et.al. Successful treatment of fungal peritonitis with intracatheter antifungal retention. Adv.Perit.Dial. 11:172-175:172-175, 1995. 285. Lee, S.H., Chiang, S.S., Hseih, S.J., and Shen, H.M. Intracatheter amphotericin B retention for fungal peritonitis in continuous ambulatory peritoneal dialysis. J.Formos.Med.Assoc. 94:132-134:132-134, 1995. 286. Leekey, D.J., Reid, R., Chan, A.G., and et.al. Cefoperazone in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients. Artif.Organs 12:482-483:482-483, 1988. 287. Lempert, K.D. and Jones, J.M. Flucytosine-miconazole treatment of candida peritonitis. Its use during continuous ambulatory peritoneal dialysis. Arch.Intern.Med. 142:577-578:577-578, 1982. 288. Leung, A.C.T., Orange, G., Henderson, I.S., and Kennedy, A.C. Diphtheroid peritonitis associated with continuous ambulatory peritoneal dialysis. Clin.Nephrol. 22:200-205:200-205, 1984. 289. Leung, A.C.T., Orange, G., Henderson, I.S., and Sleigh, J.D. Successful use of combined intraperitoneal azlocillin and aminoglycoside in the treatment of dialysis associated pseudomonas peritonitis. Perit.Dial.Bull. 5:98-101:98-101, 1984. 290. Levine, J., Bernard, D.B., Idelson, B.A., Farnham, H., Saunders, C., and Sugar, A.M. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: Successful treatment with fluconazole, a new orally active antifungal agent. Am.J.Med. 86:825-827:825-827, 1989. 291. Levison, M.E. New dosing regimens for aminoglycoside antibiotics. Ann.Intern.Med. 117:693-694:693-694, 1992. 292. Lewis, S.L., Keller, D.W., Tzamaloukas, A.H., Hallin, G.W., Merlin, T.L., and Palmer, D.L. CAPD peritonitis with unspeciated rapidly growing mycobacteria and unusual blood and peritoneal lymphocytes. Perit.Dial.Int. 14:280-282:280-282, 1994. 293. Lewis, S.L., Young, S.A., Wood, B.J., Morgan, K.S., Erickson, D.G., and Holmes, C.J. Relationship between frequent episodes of peritonitis and altered immune status. Am.J.Kidney Dis. 22:456-461:456-461, 1993. 294. Linton, I.M., Leahy, S.I., and Thomas, G.W. Mycobacterium gastri peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis. Aust.N.Z.J.Med. 16(2):224-225, 1986. 295. Locatelli, A., Quiroga, M.A., De Benedetti, L., and et.al. Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter. Adv.Perit.Dial. 11:177-179:177-179, 1995. 296. Lomaestro, B.M. and Bailie, G.R. Absorption interactions with fluroquinolones: 1995 update. Drug Safety. 12:314-337:314-337, 1995. 297. Lopes, J.O., Alves, S.H., Benevenga, J.P., and Rosa, A.C. The second case of peritonitis due to Histoplasma capsulatum during continuous ambulatory peritoneal dialysis in Brazil. Mycoses. 37:161-163:161-163, 1994. 298. Low, C.L., Bailie, G.R., Evans, A., Eisele, G., and Venezia, R.A. Pharmacokinetics of once-daily intraperitoneal gentamicin in continuous ambulatory peritoneal dialysis patients. Perit.Dial.Int. , 1996. 299. Lowy, F.D. and Hammer, S.M. Staphylococcus epidermidis infections. Ann.Intern.Med. 99:834-839:834-839, 1983. 300. Lubrich-Birkner, I., Schollmeyer, P., and Bohler, J. Carrier-status for nasal staphylococci does not predict infections in CAPD patients. Adv.Perit.Dial. 10:154-157:154-157, 1994. 301. Ludlam, H., Dickens, A., Simpson, A., and Phillips, I. A comparison of four culture methods for diagnosing infection in continuous ambulatory peritoneal dialysis. J.Hosp.Infect. 16:263-269:263-269, 1990. 302. Ludlam, H. and Barton, I. Intraperitoneal treatment of CAPD peritonitis with ciprofloxacin. J.Antimicrob.Chemother. 24:621-622:621-622, 1989. 303. Ludlam, H.A., Barton, I., White, L., McMullin, C., King, A., and Phillips, I. IP ciprofloxacin for the treatment of peritonitis in patients receiving CAPD. J.Antimicrob.Chemother. 25:843-851:843-851, 1990. 304. Ludlam, H.A., Price, T.N.C., Berry, A.J., and Phillips, I. Laboratory diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis. J.Clin.Microbiol. 26:1757-1762:1757-1762, 1988. 305. Lum, G.M. Peritonitis in infants and children on CAPD/CCPD. Martinius.Nijhoff,.Amsterdam. 189-200-200, 1987. 306. Luzar, M.A., Coles, G.A., Faller, B., Slingeneyer, A., Dah, G.D., Briat, C., Wone, C., Knefati, Y., Kessler, M., and Peluso, F. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N.Engl.J.Med. 322:505-509:505-509, 1990. 307. Lye, W.C., Leong, S.O., and Lee, E.J.C. Methicillin-resistant Staphylococcus aureus nasal carriage and infections in CAPD. Kidney Int. 43:1357-1362:1357-1362, 1996. 308. Lye, W.C., Wong, P.L., van der Straaten, J.C., Leong, S.O., and Lee, E.J.C. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Adv.Perit.Dial. 11:179-181:179-181, 1995. 309. Lye, W.C. and Leong, S.D. Neurotoxicity associated with intraperitoneal ceftazidime therapy in a CAPD patient. Perit.Dial.Int. 14:408-409:408-409, 1994. 310. Lye, W.C., Leong, S.O., van der Straaten, J., and Lee, E.J. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. Adv.Perit.Dial. 10:163-165:163-165, 1994. 311. Lye, W.C., Wong, P.L., Leong, S.O., and Lee, E.J. Isolation of organisms in CAPD peritonitis: a comparison of two techniques. Adv.Perit.Dial. 10:166-168:166-168, 1994. 312. Lye, W.C., Lee, E.J., Leong, S.O., and Kumarasinghe, G. Clinical characteristics and outcome of Acinetobacter infections in CAPD patients. Perit.Dial.Int. 14:174-177:174-177, 1994. 313. Lye, W.C., Leong, S.O., van der Straaten, J.C., and et.al. A prospective study of peritoneal dialysis-related infections in CAPD patients with diabetes mellitus. Adv.Perit.Dial. 9:195-197:195-197, 1993. 314. Lye, W.C., Lee, E.J., and van der Straaten, J. Intraperitoneal vancomycin/oral pefloxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit.Dial.Int. 13 Suppl 2:S348-50:S348-50, 1993. 315. Lynn, W.A., Clutterbuck, E., Want, S., Markides, V., Lacey, S., Rogers, T.R., and Cohen, J. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin [letter]. Lancet 344:1025-1026:1025-1026, 1994. 316. Maher, J.F. Pharmacological considerations for PD. Perit.Dial.Int. 13(Suppl 2):S363-S366, 1993. 317. Maher, J.F. Influence of continuous ambulatory peritoneal dialysis on elimination of drugs. Perit.Dial.Bull. 7:159-167:159-167, 1987. 318. Maiorca, R., Cantaluppi, A., Cancarini, G.C., Scalamogna, A., Broccoli, R., Graziani, G., Brasa, S., and Ponticelli, C. Prospective controlled trial of Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Lancet 2:642-644:642-644, 1983. 319. Mallat, S.G. and Brensilver, J.M. Tuberculosis peritonitis in CAPD patient cured without catheter removal: case report and review of the literature, and guidelines for treatment and diagnosis. Am.J.Kidney Dis. 13:154-157:154-157, 1989. 320. Mandell, I.N., Ahern, M.J., Kliger, A.S., and Andriole, V.T. Candida peritonitis complicating peritoneal dialysis: Successful treatment with low dose amphotericin B therapy. Clin.Nephrol. 6:492-496:492-496, 1976. 321. Manili, L., Brunori, G., Camerini, C., Spitti, C., Cancarini, G.C., and Maiorca, R. Low incidence of peritonitis with the T-set. Adv.Perit.Dial. 10:147-149:147-149, 1994. 322. Mansoor, G.A. and Ornt, D.B. Cryptococcal peritonitis in peritoneal dialysis patients: a case report. Clin.Nephrol. 41:230-232:230-232, 1994. 323. Manuel, M.A., Paton, T.W., and Cornish, W.R. Drugs and peritoneal dialysis. Perit.Dial.Bull. 117-125-125, 1983. 324. Matousovic, K., Moravek, J., Vitko, S., Prat, V., and Horcickova, M. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in patients undergoing CAPD. Perit.Dial.Bull. 6:33-35:33-35, 1985. 325. McGuire, N.M., Port, F.K., and Kauffman, C.A. Ketoconazole pharmacokinetics in continuous ambulatory peritoneal dialysis. Perit.Dial.Bull. 5:199-201:199-201, 1984. 326. McIntosh, M.E., Smith, W.G.J., Junor, B.J.R., Forrest, G., and Brodie, M.J. Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis. Eur.J.Clin.Pharmacol. 28:187-191:187-191, 1985. 327. McIntosh, M.E., Smith, W.G.J., Junor, B.J.R., Forrest, G., and Brodie, M.J. The effect of peritonitis on the distribution of cefuroxime in patients undergoing continuous ambulatory peritoneal dialysis. Scott.Med.J. 29:117-118:117-118, 1984. 328. Mesnard, R., Corvisier, J.M., Sire, J.M., Pouedras, P., Donnio, P.Y., and Avril, J.L. Continuous ambulatory peritoneal dialysis: evaluation of three new culture methods. Ann.Biol.Clin.(Paris) 51:697-700:697-700, 1993. 329. Michel, C., al Khayat, R., Viron, B., and et.al. How to diagnose and treat peritoneal infections in patients with terminal chronic renal insufficiency treated by peritoneal dialysis. Nephrologie. 16:55-69:55-69, 1995. 330. Miles, A.M. and Barth, R.H. Aspergillus peritonitis: therapy, survival, and return to peritoneal dialysis. Am.J.Kidney Dis. 26:80-83:80-83, 1995. 331. Millikin, S.P., Matzke, G.R., and Keane, W.F. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit.Dial.Int. 11:252-260:252-260, 1991. 332. Milutinovic, S., Varlaj, V., Molnar, V., Petrinec, D., Janicijevic, S., and Davila, D. Pharmacokinetics of ceftazidime in patients undergoing CAPD. Perit.Dial.Bull. 7(Suppl):S53, 1987. 333. Mion, C., Slingeneyer, A., and Canaud, B. Peritonitis. Churchill.Livingstone,.New York. 163-217-217, 1986. 334. Mistry, C.D., Salgia, P., Manos, J., Tooth, A., Ramsden, R.T., Marsden, A., and Gokal, R. Netilmicin (N) and vancomycin (V) in the treatment of peritonitis in patients on CAPD. Abstracts.of.the.European.Dialysis.and.Transplant.Association. -, 1985. 335. Mistry, D.D., Salgia, P., Manos, J., Tooth, A., Ramsden, R.T., Marsden, A., and Gokal, R. Netilmicin (N) and vancomycin (V) in the treatment of peritonitis in patients on CAPD. Abstracts.of.the.European.Dialysis.and.Transplant.Association. -, 1985. 336. Moncrief, J.W., Popovich, R.P., Broadrick, L.J., and et.al. The Moncrief-Popovich catheter. A new peritoneal access technique for patients on peritoneal dialysis. ASAIO.J. 39:62-65:62-65, 1993. 337. Montenegro, J., Aguirre, R., Gonzalez, O., Martinez, I., and Saracho, R. Fluconazole treatment of candida peritonitis with delayed removal of the peritoneal dialysis catheter. Clin.Nephrol. 44:60-63:60-63, 1995. 338. Moore, D., O'Brien, A.A.J., and Keogh, J.A.B. The pharmacokinetics of a single intravenous injection of teicoplanin 400 mgs. in CAPD patients. Perit.Dial.Bull. 7:S54-S54:S54, 1987. 339. Morduchowicz, G., Van Dyk, D.J., Wittenberg, C., and et.al. Bacteremia complicating peritonitis in peritoneal dialysis patients. Am.J.Nephrol. 13:278-280:278-280, 1993. 340. Morse, G., Janicke, D., Cafarell, R., Piontek, K., Apicella, M., Jusko, W.J., and Walshe, J. Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 38:140-156:140-156, 1985. 341. Morse, G.D., Apicella, M.A., and Walshe, J.J. Absorption of intraperitoneal antibiotics. Drug Intell.Clin.Pharm. 22:58-61:58-61, 1988. 342. Morse, G.D., Nairn, D.K., and Walshe, J.J. Once weekly intraperitoneal therapy for Gram-positive peritonitis. Am.J.Kidney Dis. 10:300-305:300-305, 1987. 343. Morse, G.D., Farolino, D.F., Apicella, M.A., and Walshe, J.J. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 31:173-177:173-177, 1987. 344. Morse, G.D., Lane, T., Nairn, D.K., Deterding, J., Curry, J., and Gal, P. Peritoneal transport of cefonicid. Antimicrob.Agents Chemother. 31:292-294:292-294, 1987. 345. Morse, G.D., Rowinski, C., Lieveld, P.E., and Walshe, J.J. Drug-protein binding during continuous ambulatory peritoneal dialysis. Perit.Dial.Bull. 6:144-147:144-147, 1986. 346. Morse, G.D., Janicke, D.M., Cafarell, R.F., Apicella, M.A., Jusko, W.J., Venuto, R.C., and Walshe, J.J. IP administration of moxalactam during CAPD. Field,.Rich.and.Associates,.Inc.New York. 135-140-140, 1986. 347. Morse, G.D., Lieveld, P.E., Apicella, M.A., and Walshe, J.J. Intraperitoneal cefamandole kinetics in continuous ambulatory peritoneal dialysis (CAPD) patients with and without peritonitis. Clin.Pharmacol.Ther. 37:214-214:214, 1985. 348. Morton, A.R., Waldek, S., and Holmes, A.M. Management of exit-site infections during continuous ambulatory peritoneal dialysis. Lancet i:1258-1258:1258, 1987. 349. Morton, A.R., Holmes, A.M., and Waldek, S. Rifampin plus an antistaphylococcal agent in the treatment of CAPD catheter-associated exit site infection. Perit.Dial.Bull. 6:S13-S13:S13, 1986. 350. Mrhar, A., Karba, R., Drinovec, J., Primozic, S., Varl, J., and Zozjek, F. Computer simulation of ciprofloxacin pharmacokinetics in patients on CAPD. Int.J.Artif.Organs 13(3):169-175, 1990. 351. Mulhern, J.G., Braden, G.L., O'Shea, M.H., Madden, R.L., Lipkowitz, G.S., and Germain, M.J. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am.J.Kidney Dis. 25:611-615:611-615, 1995. 352. Munch, R., Steurer, J., Luthy, R., Siegenthaler, W., and Kuhlmann, U. Serum and dialyzate concentrations of intraperitoneal cephalothin in patients undergoing continuous ambulatory peritoneal dialysis. Clin.Nephrol. 20:40-43:40-43, 1983. 353. Nakahama, H., Tanaka, Y., Shirai, D., Miyazaki, M., Imai, N., Yokokawa, T., Okada, M., and Kubori, S. Plasma interleukin-6 levels in continuous ambulatory peritoneal dialysis and hemodialysis patients. Nephron 61:132-134:132-134, 1992. 354. Neal, D. and Bailie, G.R. Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis. Clin.Pharmacokinet. 18:485-490:485-490, 1990. 355. Neale, T.J., Malani, J., and Humble, M. Netilmicin in the treatment of clinical peritonitis in chronic renal failure patients managed by continuous ambulatory peritoneal dialysis. N.Zealand.Med.J. 100:374-377:374-377, 1987. 356. Neville, L.O., Baillod, R.A., Brumfitt, W., and Hamilton-Miller, J.M.T. Efficacy and safety of teicoplanin in Gram-positive peritonitis in patients on peritoneal dialysis. J.Antimicrob.Chemother. 21((Suppl A):123-131, 1988. 357. Newman, L.N., Tessman, M., Hanslik, T., Schulak, J., Mayes, J., and Friedlander, M. A retrospective view of factors that affect catheter healing: Four years of experience. Adv.Perit.Dial. 9:217-222:217-222, 1993. 358. Nguyen, M.H. and Muder, R.R. Aspergillus peritonitis in a continuous ambulatory peritoneal dialysis patient. Case report and review of the literature. Diagn.Microbiol.Infect.Dis. 20:99-103:99-103, 1994. 359. Nguyen, V., Swartz, R.D., Reynolds, J., Wilson, D., and Port, F.K. Successful treatment of Pseudomonas peritonitis during continuous ambulatory peritoneal dialysis. Am.J.Nephrol. 7:38-43:38-43, 1987. 360. Nikolaidis, P.P. Quinolones: pharmacokinetics and pharmacodynamics. Perit.Dial.Int. 13(Suppl 2):S377-S379, 1993. 361. Nikolaidis, P.P., Vas, S., Lawson, V., Kennedy-Vosu, L., Bernard, A., Abraham, G., Izatt, S., Khanna, S., Bargman, J.M., and Oreopoulos, D.G. Is intraperitoneal tobramycin ototoxic in CAPD patients? Perit.Dial.Int. 11:156-161:156-161, 1991. 362. Nikolaidis, P.P. Newer quinolones in the treatment of CAPD related infections. Perit.Dial.Int. 10:127-129:127-129, 1990. 363. Noble, W.C., Virani, Z., and Cree, R. Co-transfer of vancomycin and other resistance genes from Enterococcus fecalis NCTC12201 to Staphylococcus aureus. FEMS Microbiol.Lett. 72:195-198:195-198, 1992. 364. Nolph, K.D., Lindblad, A.S., and Novak, J.W. Current concepts. Continuous ambulatory peritoneal dialysis. Clinical Coordinating Center, National Institutes of Health Continuous Ambulatory Peritoneal Dialysis Registry. N.Engl.J.Med. 318(24):1595-1600, 1988. 365. Nolph, K.D., Lindblad, A.S., and Novak, J.W. Continuous ambulatory peritoneal dialysis. Medical.Intell. 318:1595-1600:1595-1600, 1988. 366. Nye, K.J., Gibson, S.P., Nwosu, A.C., Manji, M.R., Robinson, B.H., and Hawkins, J.B. Single-dose intraperitoneal vancomycin and oral ciprofloxacin for the treatment of peritonitis in CAPD patients: Preliminary report. Perit.Dial.Int. 13:59-60:59-60, 1993. 367. O'Brien, M.A. and Mason, N.A. Systemic absorption of intraperitoneal antimicrobials in continous ambulatory peritoneal dialysis. Clin.Pharm. 11:246-254:246-254, 1992. 368. O'Connor, J. and MacCormick, D.E. Mixed organism peritonitis complicating continuous ambulatory peritoneal dialysi. N.Zealand.Med.J. 95:811-812:811-812, 1982. 369. Obermiller, L.E., Tzamaloukas, A.H., Leymon, P., and Avasthi, P.S. Intravenous vancomycin as initial treatment for Gram-positive peritonitis in patients on chronic peritoneal dialysis. Clin.Nephrol. 24:256-260:256-260, 1985. 370. Odds, F.C., Cheesman, S.L., and Abbott, A.B. Antifungal effects of fluconazole (UK 49858), a new triazole-antifungal, in vitro. J.Antimicrob.Chemother. 18:473-478:473-478, 1986. 371. Orin, G., Barth, R.H., Eisenberg, E., Lynn, R.I., and Soeiro, R. Antibiotic therapy and prediction of clinical response in CAPD peritonitis. Trans.Am.Soc.Artif.Intern.Organs 32:53-:53, 1986. 372. Overgaard, S., Lokkegaard, N., Scroder, S., Fugleberg, S., and Nielsen-Kudsk, F. Cefotaxime disposition pharmacokinetics during peritoneal dialysis. Pharmacol.Toxicol. 60:321-324:321-324, 1987. 373. Paap, C.M., Nahata, M.C., Menster, M.A., and et.al. Cefotaxime and metabolite disposition in two pediatric CAPD patients. Ann.Pharmacother. 26:341-343:341-343, 1992. 374. Pagniez, D., Fruchart, A., and Dequiedt, P. Group B Streptococcus and treatment of peritonitis. Nephron 71:480-:480, 1995. 375. Pagniez, D.C., MacNamara, E., Fortin, F., and et.al. Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis. B.M.J. 297:1174-1175:1174-1175, 1988. 376. Pancorbo, S. and Comty, C. Pharmacokinetics of cefamandole in patients undergoing continuous peritoneal dialysis. Perit.Dial.Bull. 4:135-137:135-137, 1983. 377. Pancorbo, S. and Comty, C. Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis. Nephron 31:37-39:37-39, 1982. 378. Pancorbo, S. and Comty, C. Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 19:605-607:605-607, 1981. 379. Pasadakis, P., Thodis, E., Eftimimiadou, A., Panagoutsos, S., Papazoglou, D., Kaliengidou, M., Kartali, S., and Vargemezis, V. Treatment and prevention of relapses of CAPD Pseudomonas peritonitis. Adv.Perit.Dial. 9:206-210:206-210, 1993. 380. Pasadakis, P., Vargemezis, V., Thodis, E., Gogou, G., Peinaberis, P., and Jafer, H. Ceftazimide as montherapy in CAPD peritonitis. Perit.Dial.Intl. 9:136-:136, 1989. 381. Pascual, A., Ramirez de Arellano, E., Martinez, M.L., and Perea, E.J. Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis. J.Hosp.Infect. 24(3):211-218, 1993. 382. Paton, T.W., Manuel, M.A., and Walker, S.E. Tobramycin disposition in patients on continuous ambulatory peritoneal dialysis. Perit.Dial.Bull. 4:179-181:179-181, 1989. 383. Paton, T.W., Cornish, W.R., Manuel, M.A., and Hardy, B.G. Drug therapy in patients undergoing peritoneal dialysis. Clin.Pharmacokinet. 10:404-426:404-426, 1985. 384. Paton, T.W., Manuel, A., Cohen, L.B., and Walker, S.E. The disposition of cefazolin and tobramycin following intraperitoneal administration in patients on continuous ambulatory peritoneal dialysis. Perit.Dial.Bull. 3:73-76:73-76, 1983. 385. Peer, G., Serban, I., Blum, B., and et.al. Early diagnosis of gram-negative peritonitis in continuous ambulatory peritoneal dialysis patients with the lymulus amebocyte lysate assay. Am.J.Nephrol. 12:19-21:19-21, 1992. 386. Pennington, J.C.,3rd, Hauer, K., and Miller, W. Rhodotorula Rubra peritonitis in an HIV+ patient on CAPD. Del.Med.J. 67:184-184:184, 1995. 387. Perazella, M., Eisen, T., and Brown, E. Peritonitis associated with disseminated Mycobacterium avium complex in an acquired immunodeficiency syndrome patient on chronic ambulatory peritoneal dialysis. Am.J.Kidney Dis. 21:319-321:319-321, 1993. 388. Perez-Fontan, M., Rosales, M., Rodriguez-Carmona, A., Garcia Falcon, T., Adeva, M., Fernandez Rivera, C., and Moncalian, J. Treatment of peritonitis in CAPD with ciprofloxacin: long-term experience. Adv.Perit.Dial. 9:211-214:211-214, 1993. 389. Perez-Fontan, M., Garcia-Falcon, T., Rosales, M., Rodriguez-Carmona, A., Adeva, M., Rodriguez-Lozano, I., and Moncalian, J. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am.J.Kidney Dis. 22:708-712:708-712, 1993. 390. Perez-Fontan, M., Rosales, M., Fernandez, F., Moncalian, J., Fernandez-Rivera, C., Alonso, A., and Valdes, F. Ciprofloxacin in the treatment of gram-positive bacterial peritonitis in patients undergoing CAPD. Perit.Dial.Int. 11:233-236:233-236, 1991. 391. Perry, G., Mant, T.G.K., Morrison, P.J., and et.al. Pharmacokinetics of rufloxacin in patients with impaired renal function. Antimicrob.Agents Chemother. 37:637-641:637-641, 1993. 392. Petersen, J., Stewart, R.D.M., Catto, G.R.D., and Edward, N. Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continous ambulatory peritoneal dialysis. Nephron 40:79-82:79-82, 1985. 393. Peterson, J., Stewart, R.D.M., Catto, G.R.D., and Edward, N. Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Nephron 40:79-82:79-82, 1985. 394. Peterson, P.K., Matzke, G., and Keane, W.F. Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev.Infect.Dis. 9:604-612:604-612, 1987. 395. Peterson, P.K., Lee, D., Suh, H.J., Devalon, M., Nelson, R.D., and Keane, W.F. Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. Am.J.Kidney Dis. 7:146-152:146-152, 1986. 396. Peterson, P.K., Gaziano, E., Devalon, M., Peterson, L.A., and Keane, W.F. Antimicrobial activities of dialysate elicited and resident human peritoneal macrophages. Infect.Immun. 49:212-218:212-218, 1985. 397. Peterson, P.K., Gekker, G., Shapiro, R., Freiberg, M., and Keane, W.F. Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages. Infect.Immun. 43:561-566:561-566, 1984. 398. Peterson, P.K., Keane, W.F., Miller, W., Freiberg, M., Staub, D., and Verbrugh, H.A. Human peritoneal macrophage cytotoxicity mediated by cytophilic IgG. J.Infect.Dis. 148:1040-1048:1040-1048, 1983. 399. Phan, H.T., Evans, J.R., and Cutler, R.E. Monodrug therapy for CAPD-associated peritonitis (CAP). Perit.Dial.Bull. 6:S15-S15:S15, 1986. 400. Phillips, G., Fleming, L.W., and Stewart, W.K. Psseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilimicin. Eur.J.Clin.Microbiol.Infect.Dis. 9:630-631:630-631, 1990. 401. Pignatari, A., Pfaller, M., Hollis, R., Sesso, R., Leme, I., and Herwaldt, L. Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J.Clin.Microbiol. 28:1898-1902:1898-1902, 1990. 402. Piraino, B., Perlmutter, J.A., Holley, J.L., and Bernardini, J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit.Dial.Int. 13((suppl 2):S332-S334, 1993. 403. Piraino, B., Bernardini, J., Holley, J.L., and Perlmutter, J.A. Increased risk of staphylococcus epidermidis peritonitis in patients on dialysate containing 1.25 mmol/L calcium. Am.J.Kidney Dis. 19:371-374:371-374, 1992. 404. Piraino, B., Bernardini, J., and Sorkin, M. A five-year study of the microbiologic results of exit site infections and peritonitis in continuous ambulatory peritoneal dialysis. Am.J.Kidney Dis. 10:281-286:281-286, 1987. 405. Piraino, B., Bernardini, J., Johnston, J., and Sorkin, M. Chemical peritonitis due to intraperitoneal vancomycin (vancoled). Perit.Dial.Bull. 7:156-159:156-159, 1987. 406. Pitt, W.G., McBride, M.O., Lunceford, J.K., Roper, R.J., and Sagers, R.D. Ultrasonic enhancement of antibiotic action on gram-negative bacteria. Antimicrob.Agents Chemother. 38(11):2577-2582, 1994. 407. Plastino, K.A., Connors, J.E., and Spinler, S.A. Possible synergy between aminoglycosides and vancomycin in the treatment of Staphylococcus epidermidis endocarditis? Ann.Pharmacother. 28(6):737-739, 1994. 408. Plum, J., Sudkamp, S., and Grabensee, B. Results of ultrasound-assisted diagnosis of tunnel infections in continuous ambulatory peritoneal dialysis. Am.J.Kidney Dis. 23:99-104:99-104, 1994. 409. Pocheville, M., Charpentier, B., Brochard, J.F., Benarbia, S., Hammouche, M., and Fries, D. Successful in situ treatment of a fungal peritonitis during CAPD. Nephron 37:66-67:66-67, 1984. 410. Polk, R.E. Comment: aminoglycoside dosing considerations. Ann.Pharmacother. 27:982-983:982-983, 1993. 411. Polo, J.R., Luno, J., Menarguez, C., Gallego, E., Robles, R., and Hernandez, P. Peritoneal mucormycosis in a patient receiving continuous peritoneal dialysis. Am.J.Kidney Dis. 13:237-239:237-239, 1989. 412. Poole-Warren, L.A. and Farrell, P.C. The role of vaccination in the prevention of staphylococcal peritonitis in continuous ambulatory peritoneal dialysis [editorial]. Perit.Dial.Int. 13:176-177:176-177, 1993. 413. Powell, D., San Luis, E., Calvin, S., McDaid, T., and Potter, D. Peritonitis in children undergoing continuous ambulatory peritoneal dialysis. Am.J.Dis.Child 139:29-32:29-32, 1985. 414. Prins, J.M., Buller, H.R., Kuijper, E.J., Tange, R.A., and Speelman, P. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial. J.Antimicrob.Chemother. 33:823-835:823-835, 1994. 415. Prins, J.M., Buller, H.R., Kuijper, E.J., Tange, R.A., and Speelman, P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 341:335-339:335-339, 1993. 416. Prokesch, R.C. and Hand, W.L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob.Agents Chemother. 21:373-380:373-380, 1982. 417. Prowant, B.F., Warady, B.A., and Nolph, K.D. Peritoneal dialysis catheter exit-site care: Results of an itnernational survey. Perit.Dial.Int. 13:149-154:149-154, 1993. 418. Querin, S. and Poisson, M. Cefamandole and netilmicin as first line therapy of CAPD-related peritonitis. Perit.Dial.Bull. 7((Suppl):S61, 1987. 419. Ramello, A., Malcangi, U., Bruno, M., Gariglio, M., and Martinetto, P. Studies on ceftriaxone (cx) pharmacokinetics and clinical parameters during CAPD peritonitis: a comparison of 3 different administration methods. Perit.Dial.Bull. 6:263-263:263, 1985. 420. Rasnid, A., Limpach, D., and Bacani, R.A. Continuous ambulatory peritoneal dialysis (C.A.P.D.) in high risk and immunosuppressed patients - the role of prophylactic antibiotics. Perit.Dial.Intl. 9:-, 1989. 421. Rayner, B.L., Williams, D.S., and Oliver, S. Innoculation of peritoneal dialysate fluid into blood culture bottles improves culture rates. S.Afr.Med.J. 83:42-43:42-43, 1993. 422. Read, R.R., Eberwein, P., Dasgupta, M.K., Grant, S.K., Lam, K., Nickel, J.C., and Costerton, J.W. Peritonitis in peritoneal dialysis: bacterial colonization by biofilm spread along catheter surface. Kidney Int. 35:614-621:614-621, 1989. 423. Reitinger, J., Schirmeister, J., and Paatz, D. Minimal inhibition concentration of a chinolon derivate (ofloxacin) in CAPD patients. Perit.Dial.Bull. 6:S16-S16:S16, 1986. 424. Reuman, P.D., Neiberger, R., and Kondor, D.A. Intraperitoneal and intravenous fluconazole pharmacokinetics in a pediatric patient with end-stage renal disease. Pediatr.Infect.Dis.J. 11:132-133:132-133, 1992. 425. Richards, G.K. and Gagnon, R.F. The differential activity of aminoglycoside antibiotics with rifampin explored in a kinetic in vitro model of implant-associated infection (Staphylococcus epidermidis). Adv.Perit.Dial. 10:183-188:183-188, 1994. 426. Richards, G.K. and Gagnon, R.F. An assay of Staphylococcus epidermidis biofilm responses to therapeutic agents. Int.J.Artif.Organs 16(11):777-788, 1993. 427. Robitaille, P., Merouani, A., Clermont, M.J., and Hebert, E. Successful antifungal prophylaxis in chronic peritoneal dialysis: a pediatric experience. Perit.Dial.Int. 15:77-79:77-79, 1995. 428. Rogge, M.C., Johnson, C.A., Zimmerman, S.W., and Welling, P.G. Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport. Antimicrob.Agents Chemother. 27:578-582:578-582, 1985. 429. Rose, T.F., Ellis-Pegler, R., Collins, J., and Small, M. Oral pefloxacin mesylate in the treatment of continuous ambulatory peritoneal dialysis associated peritonitis: an open non-comparative study. J.Antimicrob.Chemother. 25:853-859:853-859, 1990. 430. Rottembourg, J., Singlas, E., Colin, J.M., and Meessen, J.P. Co-trimoxazole, as treatment of first choice in peritonitis during peritoneal dialysis. Proceedings.of.the.20th.Interscience.Conference.on.Antimicrobial.Agents and.Chem. -, 1980. 431. Rowe, L., Findon, G., and Miller, T.E. An experimental evaluation of the pharmacokinetics of fusidic acid in peritoneal dialysis. J.Med.Microbiol. 36:71-77:71-77, 1992. 432. Rubin, J., Kirschner, K., Walsh, D., Green, M., and Bower, J. Fungal peritonitis during continuous ambulatory peritoneal dialysis: A report of 17 cases. Am.J.Kidney Dis. 10:361-368:361-368, 1987. 433. Rubin, J., Lin, L.M., Lewis, R., Cruse, J., and Bower, J.D. Host defense mechanisms in continuous ambulatory peritoneal dialysis. Clin.Nephrol. 20:140-144:140-144, 1983. 434. Rubin, J., Rogers, W.A., Taylor, H.M., Everett, E.D., Prowant, B.F., Fruto, L.V., and Nolph, K.D. Peritonitis during continuous ambulatory peritoneal dialysis. Ann.Intern.Med. 92:7-13:7-13, 1980. 435. Rubin, S.J. Continuous ambulatory peritoneal dialysis: dialysate fluid cultures. Clin.Microbiol.Newsl. 6:3-5:3-5, 1984. 436. Ruoff, K.L., Kuritzkes, D.R., Wolfson, J.S., and Ferraro, M.J. Vancomycin-resistant Gram-positive bacteria isolated from human sources. J.Clin.Microbiol. 26:2064-2068:2064-2068, 1988. 437. Ryckelynck, J.P., de Ligny, B.H., and Vergnaud, M. Pharmacokinetics of ceftazidime in patients on CAPD. Perit.Dial.Bull. 6:108-108:108, 1986. 438. Sanyal, D., Williams, A.J., Johnson, A.P., and George, R.C. The emergence of vancomycin resistance in renal dialysis. J.Hosp.Infect. 24:167-173:167-173, 1993. 439. Scalamogna, A., Castelnovo, C., De Vecchi, A., and Ponticelli, C. Exit-site and tunnel infections in continuous ambulatory peritoneal dialysis patients. Am.J.Kidney Dis. 18(6):674-677, 1991. 440. Schleifer, C.R. and Moran, D. How much vancomycin (V) is enough for Gram-positive peritonitis (GPP)? Perit.Dial.Intl. 161-, 1989. 441. Schmit, J.L., Hary, L., Bou, P., Renaud, H., Westeel, P.F., Andrejak, M., and Fournier, A. Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on continous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 35:1492-1494:1492-1494, 1991. 442. Schroder, C.H., Severijnen, R.S.V.M., de Jong, M.C.J.W., and Monnens, L.A.H. Chronic tunnel infections in children: Removal and replacement of the continuous ambulatory peritoneal dialysis catheter in a single operation. Perit.Dial.Int. 13:198-200:198-200, 1993. 443. Schurig, R., Kampf, D., Spieber, W., Weihermuller, K., and Becker, H. Cefotaxime pharmacokinetics in Peritoneal dialysis (PD). Excerpto.Medica,.Amsterdam. 96-91-91, 1981. 444. Schwalbe, R.S., Stapleton, J.T., and Gilligan, P.H. Emergence of vancomycin resistance in coagulase-negative staphylococci. Medical.Intell. 316:927-931:927-931, 1987. 445. Schwartz, M.T., Kowalsky, S.F., McCormick, E.M., Parker, M.A., and Echols, R.M. Clindamycin phosphate kinetics in subjects undergoing CAPD. Clin.Nephrol. 26:303-306:303-306, 1986. 446. Scott, A.C., Fleming, L.W., and Stewart, W.K. Efficacy of ciprofloxacin in treatment of CAPD peritonitis. Eur.J.Clin.Microbiol. 6:599-:599, 1987. 447. Searle, M. and Raman, G.V. Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Clin.Nephrol. 23:241-244:241-244, 1985. 448. Sennesael, J.J., Maes, V.A., Pierard, D., Debeukelaer, S.H., and Verbeelen, D.L. Streptomycin pharmacokinetics in relapsing mycobacterium xenopi peritonitis. Am.J.Nephrol. 9(2):155-161, 1989. 449. Sesso, R., Parisio, K., Dalboni, A., Rabelo, T., Barbosa, D., Cendoroglo, M., Pignatari, A., Draibe, S., and Ajzen, H. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clin.Nephrol. 41:370-376:370-376, 1994. 450. Sesso, R., Draibe, S., Castelo, A., Sato, I., Leme, I., Barbosa, D., and Ramos, O. Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis. Clin.Nephrol. 31:264-268:264-268, 1989. 451. Sewell, C.M., Clarridge, J., Lacke, C., Weinman, E.J., and Young, E.J. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. J.A.M.A. 248:1493-1495:1493-1495, 1982. 452. Sewell, D.L., Golper, T.A., Hulman, P.B., Thomas, C.M., West, L.M., Kubey, W.Y., and Holmes, C.J. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate. Perit.Dial.Int. 10:49-52:49-52, 1990. 453. Sewell, D.L., Golper, T.A., Brown, S.D., Nelson, E., Knower, M., and Kimbrough, R.C. Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Am.J.Kidney Dis. 3:209-213:209-213, 1983. 454. Shalit, I., Welch, D.F., San Joaquin, V., and Marks, M.I. In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid. Antimicrob.Agents Chemother. 27:908-911:908-911, 1989. 455. Shalit, I., Greenwood, R.B., Marks, M.I., Pederson, J.A., and Frederick, D.L. Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 30:152-156:152-156, 1986. 456. Sharp, B.M., Tsukayama, D., Gekker, G., Keane, W.F., and Peterson, P.K. b-Endorphin stimulates polymorphonuclear leukocyte superoxide production via a stereoselective opioid receptor. J.Pharmacol.Exp.Ther. 242:579-582:579-582, 1987. 457. Sharp, B.M., Keane, W.F., Suh, H.J., Gekker, G., Tsukayama, D., and Peterson, P.K. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. J.Endocrinol. 117:793-795:793-795, 1985. 458. Shay, D.K., Maloney, S.A., Montecalvo, M., and et.al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J.Infect.Dis. 172:993-1000:993-1000, 1995. 459. Sherbotie, J.R., Polise, K., Costarino, A., DiCarlo, J.V., and Kaplan, B.S. Toxic shock syndrome with Spahylococcus aureus exit-site infection in a patient on peritoneal dialysis. Am.J.Kidney Dis. 15:80-83:80-83, 1990. 460. Shusterman, N.H. and Jacobs, J. Management of refractory peritonitis to maintain the peritoneum for subsequent dialysis. Perit.Dial.Int. 12:211-213:211-213, 1992. 461. Sica, D.A., Polk, R.E., Kerkering, T.M., Patterson, P., and Baggett, J. Defmenoxime kinetics during continuous ambulatory peritoneal dialysis. Eur.J.Clin.Pharmacol. 30:713-717:713-717, 1986. 462. Singlas, E., Boutron, H.F., Merdjan, H., Brocard, J.F., Pocheville, M., and Fries, D. Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 34:403-407:403-407, 1983. 463. Sitter, T., Spannagl, M., Schiffl, H., Held, E., van Hinsbergh, V.W., and Kooistra, T. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells. Nephrol.Dial.Transplant. 10:677-683:677-683, 1995. 464. Slingeneyer, A., Laroche, B., Stec, F., Canaud, B., Beraud, J.J., and Mion, C. Oral ketoconazole(Ktz) plus intraperitoneal 5-fluorocytosine (5-Fl) as the sole treatment of fungal peritonitis. Perit.Dial.Bull. 4:S60-:S60, 1984. 465. Smalley, D.L., Baddour, L.M., and Kraus, A.P. Rapid detection of gram-negative bacterial peritonitis by the Limulus amoebocyte lysate assay. J.Clin.Microbiol. 24:882-883:882-883, 1986. 466. Smeltzer, B.D., Schwartzman, M.S., and Bertino, J. Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 32:236-240:236-240, 1988. 467. Sojo, E.T., Wainberg, E.S., Piantanida, J.J., Rivas, M.E., and Mendilaharzu, F. Successful treatment of a child with candida peritonitis during CAPD without removing the catheter. Perit.Dial.Bull. 6:104-105:104-105, 1986. 468. Somani, P., Freimer, E.H., Gross, M.L., and Higgins, J. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 32:530-534:530-534, 1988. 469. Somani, P., Shapiro, R.S., Stockard, H., and Higgins, J.T. Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 32:113-121:113-121, 1982. 470. Spencer, R.C. Infections in continuous ambulatory peritoneal dialysis. J.Med.Microbiol. 27:1-9:1-9, 1988. 471. Stamatakis, M.K., Sorkin, M.I., and Moss, A.H. Toxicity following IP trimethoprim-sulfamethoxazole in a CAPD patient [letter]. Perit.Dial.Int. 15:180-181:180-181, 1995. 472. Stein, A., Baker, F., Moorhouse, J., and Walls, J. Peritonitis rate: traditional versus low calcium dialysate. Am.J.Kidney Dis. 26:632-633:632-633, 1995. 473. Steinhauer, H.B. Pharmacological manipulation of peritoneal transport in CAPD. Clin.Nephrol. 30:S29-S33:S29-S33, 1988. 474. Strauss, F.G., Holmes, D.L., Nortmann, D.F., and Friedman, S. Hypertonic saline compresses: Therapy for complicated exit-site infections. Adv.Perit.Dial. 9:248-250:248-250, 1993. 475. Struijik, D.G., Krediet, R.T., Boeschoten, E.W., Rietra, P.J.G.M., and Arisz, L. Antifungal treatment of candida peritonitis in continuous ambulatory peritoneal dialysis patients. Am.J.Kidney Dis. 9:66-70:66-70, 1987. 476. Struijk, D.G., Boeschoten, E.W., Krediet, R.T., and Kuijper, E.J. Fluconazole in candida peritonitis in CAPD: an alternative proposal [letter; comment]. Nephrol.Dial.Transplant. 10:426-426:426, 1995. 477. Stuck, A.E., Frey, F.J., Heizmann, P., Brandt, R., and Weidekamm, E. Pharmcokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrob.Agents Chemother. 33:373-381:373-381, 1989. 478. Taber, T.E., Hegeman, T.F., York, S.M., Kinney, R.A., and Webb, D.H. Treatment of pseudomonas infections in peritoneal dialysis patients. Perit.Dial.Int. 11:213-216:213-216, 1991. 479. Tan, D., Fein, P.A., Jorden, A., and Avram, M.M. Successful treatment of tuberculous peritonitis while maintaining patient on CAPD. Adv.Perit.Dial. 7:102-104:102-104, 1991. 480. Tanis, B.C., van der Pijl, H., van Ogtrop, M.L., Kibbelaar, R.E., and Chang, P.C. Fatal fungal peritonitis by Trichoderma longibrachiatum complicating peritoneal dialysis. Nephrol.Dial.Transplant. 10:114-116:114-116, 1995. 481. Tanis, B.C., Verburgh, C.A., van 't Wout, J.W., and van der Pijl, J.W. Aspergillus peritonitis in peritoneal dialysis: case report and a review of the literature [see comments]. Nephrol.Dial.Transplant. 10:1240-1243:1240-1243, 1995. 482. Tapson, J.S., Orr, K.E., George, J.C., Stansfield, E., Bint, A.J., and Ward, M.K. A comparison between oral ciprofloxacin and IP vancomycin and netilicin in CAPD peritonitis. J.Antimicrob.Chemother. 26((suppl F):63-71, 1990. 483. Taylor, P.C. Routine laboratory diagnosis of continuous ambulatory peritoneal dialysis peritonitis using centrifugation/lysis and saponin-containing media. Eur.J.Clin.Microbiol.Infect.Dis. 13:249-252:249-252, 1994. 484. Teichman, J.M.H., Abraham, V.E., Stein, P.C., and et.al. Protamine sulfate and vancomycin are synergistic against staphylococcus epidermidis prosthesis infection in vivo. J.Urol. 152:213-216:213-216, 1994. 485. The Hospital Infection Control Practices Advisory Committee Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am.J.Infect.Control. 23:87-94:87-94, 1995. 486. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann.Intern.Med. 119:584-593:584-593, 1993. 487. Ti, T., Fortin, L., Kreeft, J.H., East, D.S., Ogilvie, R.I., and Somerville, P.J. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob.Agents Chemother. 25:83-87:83-87, 1984. 488. Tofte-Jensen, P., Nielsen, P.K., Klem, S., and Hemmingsen, C. Peritonitis incidence on a disconnect CAPD-system with or without the use of iodine clamp shields. Adv.Perit.Dial. 10:150-153:150-153, 1994. 489. Tofte-Jensen, P., Klem, S., Nielsen, P.K., and Olgaard, K. PD-related infections of standard and different disconnect systems. Adv.Perit.Dial. 10:214-217:214-217, 1994. 490. Traina, G.L., Gentile, M.G., Fellin, G., Rosina, R., Cavenaghi, L., Buniva, G., and Bonati, M. Teicoplanin pharmacokinetic profile in patients with chronic renal failure on CAPD. Perit.Dial.Bull. 7:S77-S77:S77, 1987. 491. Traina, G.L., Gentile, M.G., Fellin, G., Rosina, R., Cavenaghi, L., Buniva, G., and Bonati, M. Pharmcokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis. Eur.J.Clin.Pharmacol. 31:501-504:501-504, 1986. 492. Tranaeus, A., Heimbürger, O., and Lindholm, B. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): diagnostic findings, therapeutic outcome and complications. Perit.Dial.Int. 9:179-190:179-190, 1989. 493. Tranaeus, A., Heimburger, O., and Lindholm, B. Peritonitis during continuous ambulatory peritoneal dialysis (CAPD): Risk factors, clinical severity, and pathogenetic aspects. Perit.Dial.Int. 8:253-263:253-263, 1988. 494. Tsai, T.C., Hsu, J.C., Chou, L.H., and Lee, M.L. Tuberculous peritonitis in a child undergoing continuous ambulatory peritoneal dialysis. Acta Paediatr.Sin. 35(5):455-459, 1994. 495. Tsukayama, D., Breitenbucher, R., Steinberg, S., Allen, J., Nelson, R., Gekker, G., Keane, W.F., and Peterson, P.K. Polymorphonuclear leukocyte,T-lymphocyte, and natural killer cell activities in elderly nursing home residents. Eur.J.Clin.Microbiol. 5:468-4l71:468-4l71, 1986. 496. Tuazon, C.U., Perez, A., and Kishaba, T. Staphylococcus aureus among insulin-injecting diabetic patients. J.A.M.A. 231:1272-:1272, 1975. 497. Tuazon, C.U. and Sheagren, J.N. S. Endocarditis in parenteral drug abusers: source of the organism. Ann.Intern.Med. 82:788-:788, 1975. 498. Turner, E.D., Hair, M., and et.al. Does catheter immobilization reduce exit-site infections in CAPD patients? Adv.Perit.Dial. 8:265-268:265-268, 1992. 499. Tzamaloukas, A.H., Murata, G.H., and Fox, L. Peritoneal catheter loss and death in continuous ambulatory peritoneal dialysis peritonitis: correlation with clinical and biochemical parameters. Perit.Dial.Int. 13 Suppl 2:S338-40:S338-40, 1993. 500. Tzamaloukas, A.H., Obermiller, L.E., Gibel, L.J., Murata, G.H., Wood, B., Simon, D., Erickson, D.G., and Kanig, S.P. Peritonitis associated with intra-abdominal pathology in continuous ambulatory peritoneal dialysis patients. Perit.Dial.Int. 13 Suppl 2:S335-7:S335-7, 1993. 501. Tzamaloukas, A.H., Hartshorne, M.F., Gibel, L.J., and Murata, G.H. Persistence of positive dialysate cultures after apparent cure of CAPD peritonitis. Adv.Perit.Dial. 9:198-201:198-201, 1993. 502. Usberti, M., Gazzotti, R.M., Mileti, M., Brazzoli, A., Zucca, F., Depetri, G., Braga, B., and Losio, R. Treatment of acute peritonitis by temporary discontinuation of dialysis and low doses of oral ciprofloxacin in patients on CAPD. Perit.Dial.Int. 14:185-186:185-186, 1994. 503. Valainis, G.T. and Morford, D.W. Ketoconazole levels in peritoneal fluid. Perit.Dial.Bull. 6:136-137:136-137, 1985. 504. van der Hulst, R.J., Boeschoten, E.W., Nielson, F.W., and et.al. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. O.R.L. 53:19-22:19-22, 1991. 505. van Uum, S.H.M., Martea, M., Vree, T.B., and Berden, J.H.M. Levels of co-trimoxazole and cephradine after oral administration in CAPD-peritonitis. Perit.Dial.Bull. 7:S81-S81:S81, 1987. 506. Vargemezis, V., Pasadakis, P., Thodis, H., Coucudis, P., Peihaberis, P., Jafer, H., Jara, F., and Kartali, S. Vancomycin therapy for Gram-positive peritonitis in patients on CAPD. Perit.Dial.Intl. 9:-, 1989. 507. Vargemezis, V., Papadopoulou, Z.L., and Liamos, H. Management of fungal peritonitis during continuous ambulatory peritoneal dialysis(CAPD). Perit.Dial.Bull. 6:17-19:17-19, 1986. 508. Vas, S.I. Treatment of peritonitis: how are we doing? [editorial; comment]. Perit.Dial.Int. 15:201-202:201-202, 1995. 509. Vas, S.I. The diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis. Semin.Dial. 8(4):232-237, 1995. 510. Vas, S.I. Renaissance of tuberculosis in the 1990s: Lesson for the nephrologist. Perit.Dial.Int. 14:209-214:209-214, 1994. 511. Vas, S.I. Treatment of peritonitis. Perit.Dial.Int. 14 Suppl 3:S49-55:S49-55, 1994. 512. Vas, S.I. Single daily dose of aminoglycosides in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit.Dial.Int. 13 Suppl 2:S355-6:S355-6, 1993. 513. Vas, S.I. Peritonitis of peritoneal dialysis patients: Pathogenesis and treatment. Academic.Press,.London. 21-63-63, 1986. 514. Vas, S.I. and Low, L. Microbiological diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis. J.Clin.Microbiol. 21:522-523:522-523, 1985. 515. Vas, S.I. Microbiologic aspects of chronic ambulatory peritoneal dialysis. Kidney Int. 23:83-92:83-92, 1983. 516. Vas, S.I. Peritonitis during CAPD. A mixed bag. Perit.Dial.Bull. 1:47-49:47-49, 1981. 517. Verbrugh, H.A., Keane, W.F., Conroy, W.E., and Peterson, P.K. Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids. J.Clin.Microbiol. 20:1-5:1-5, 1984. 518. Verbrugh, H.A., Keane, W.F., Hoidal, J.R., Freiberg, M.R., Elliot, G.R., and Peterson, P.K. Peritoneal macrophages and opsonins: antibacterial defense in patients on chronic peritoneal dialysis. J.Infect.Dis. 147:1018-1029:1018-1029, 1983. 519. Verrina, E., Bassi, S., Perfumo, F., Edefonti, A., Zachello, G., Andreeta, B., Pela, I., Penza, R., Piaggio, G., Picca, M., and Cantaluppi, A. Analysis of complications in a chronic peritoneal dialysis pediatric patient population. Perit.Dial.Int. 13((suppl 2):S257-259, 1993. 520. Veys, N., Lameire, N., Malerczyk, V., Lehr, K.H., Rosenkranz, B., and Ringoir, S. Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis. Clin.Pharmacol.Ther. 54:395-401:395-401, 1993. 521. Vincent, F., Bensousan, T.A., and Leclercq, B. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: use of high dosages of fluconazole or solely removal of the catheter? [letter; comment]. Nephrol.Dial.Transplant. 10:141-142:141-142, 1995. 522. von Graeventiz, A. and Amsterdam, D. Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis. Clin.Microbiol.Rev. 5:36-48:36-48, 1992. 523. Wadha, N.K., Cabralda, T., Suh, H., and et.al. Exit-site/tunnel infection and catheter outcome in peritoneal dialysis patients. Adv.Perit.Dial. 8:325-327:325-327, 1992. 524. Waite, N.M., Johnson, M.D., Webster, N.R., and Fong, I.W. Poor response to oral ciprofloxacin in the treatment of peritonitis in patients on intermittent peritoneal dialysis. Perit.Dial.Int. 13:50-54:50-54, 1993. 525. Walshe, J.J. and Morse, G.D. The influence of peritonitis on the pharmacokinetics of intraperitoneal vancomycin. Kidney Int. 31:99A-99A:99A, 1987. 526. Walshe, J.J., Morse, G.D., Janicke, D.M., and Apicella, M.A. Crossover pharmacokinetic analysis comparing intravenous and intraperitoneal administration of tobramycin. J.Infect.Dis. 153:796-799:796-799, 1986. 527. Warady, B.A., Sullivan, E.K., and Alexander, S.R. Lessons from the peritoneal dialysis patient data base: a report of the North American Pediatric Renal Transplant Cooperative Study. Kidney Int. 49((supp 53):S68-S71, 1996. 528. Warady, B.A., Campoy, S.F., Gross, S.P., Sedman, A.B., and Lum, G.M. Peritonitis with continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis. J.Pediatr. 105:726-730:726-730, 1984. 529. Ward, K.H., Olson, M.E., Lam, K., and Costerton, J.W. Mechanism of persistent infection associated with peritoneal implants. J.Med.Microbiol. 36(6):406-413, 1992. 530. Watanakunakorn, C. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin. J.Antimicrob.Chemother. 22:321-324:321-324, 1988. 531. Watson, A.R., Vigneux, A., Bannatyne, R.M., and Balfe, J.W. Peritonitis during continuous ambulatory peritoneal dialysis in children. CMAJ. 134:1019-1022:1019-1022, 1986. 532. Watson, C.J., Finlay-Jones, J.J., McDonald, P.J., and Hart, P.H. IL-4 mRNA expression by peritoneal cells during episodes of peritonitis in patients on continuous ambulatory peritoneal dialysis. Clin.Exp.Immunol. 100:253-261:253-261, 1995. 533. Weaver, M.E. and Dunbeck, D.C. Mupirocin (Bactroban) causes permanent structural changes in peritoneal dialysis catheters. Perit.Dial.Int. 14(Suppl 1):S20, 1994. 534. Weber, J. and Kuhlmann, U. Intraperitoneal cefazolin and gentamicin in the management of CAPD-related peritonitis. Contrib.Nephrol. 89:108-118:108-118, 1991. 535. Weber, J., Staerz, E., Mettang, T., Machleidt, C., and Kuhlmann, U. Treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) with intraperitoneal cefazolin and gentamicin. Perit.Dial.Int. 9:191-195:191-195, 1989. 536. Weissauer-Condon, C., Engels, I., and Daschner, F.D. In vitro activity of four new quinolones in Mueller-Hinton broth and peritoneal dialysis fluid. Eur.J.Clin.Microbiol. 6:324-326:324-326, 1987. 537. Were, A.J., Marsden, A., Tooth, A., and et.al. Netilmicin and vancomycin in the treatment of peritonitis in CAPD patients. Clin.Nephrol. 37:209-213:209-213, 1992. 538. Whitby, M., Edwards, R., Aston, E., and Finch, R.G. Pharmacokinetics of single dose intravenous vancomycin in CAPD peritonitis. J.Antimicrob.Chemother. 19:351-357:351-357, 1987. 539. White, R., Abreo, K., Flanagan, R., Gadallah, M., Krane, K., el-Shahawy, M., Shakamuri, S., and McCoy, R. Non-tuberculous mycobacterial infections in continuous ambulatory peritoneal dialysis patients. Am.J.Kidney Dis. 232:581-587:581-587, 1993. 540. Wilcos, M.H. and Finch, R.G. Ciprofloxacin and peritonitis. J.Antimicrob.Chemother. 26:447-448:447-448, 1990. 541. Williams, P., Swift, S., and Modun, B. Continuous ambulatory peritoneal dialysis-associated peritonitis as a model device-related infection: phenotypic adaptation, the staphylococcal cell envelope and infection. J.Hosp.Infect. 30 Suppl:35-43:35-43, 1995. 542. Williams, R.E.O. Health carriage of S. aureus: its prevalence and importance. Bacteriol.Rev. 27:56-:56, 1963. 543. Winslow, D.L. and Steele, M.L. Listeria bacteremia and peritonitis associated with a peritoneovenous shunt: successful treatment with sulfamethoxazole and trimethoprim. J.Infect.Dis. 149:-, 1984. 544. Yinnon, A.M., Solages, A., and Treanor, J.J. Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin.Infect.Dis. 17:736-741:736-741, 1993. 545. Yu, V.L., Goetz, A., Wagener, M., Smith, P.B., Rihs, J.D., Hanchett, J., and Zuravleff, J.J. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N.Engl.J.Med. 315:91-96:91-96, 1986. 546. Zaruba, K., Peters, J., and Jungbluth, H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. Am.J.Kidney Dis. 17(1):43-46, 1991. 547. Zimmerli, W., Frei, R., Widmer, A.F., and Rajacic, Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J.Antimicrob.Chemother. 33(5):959-967, 1994. 548. Zimmerman, S.W., Ahrens, E., Johnson, C.A., and et.al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis related infections. Am.J.Kidney Dis. 18:225-231:225-231, 1991. 549. Zimmerman, S.W., Ahrens, E., Johnson, C.A., Craig, W., Leggett, J., O'Brien, M., Oxton, L., Roecker, E., and Engeseth, S. Randomized, controlled trial of prophylactic rifampin for PD catheter-related infections and peritonitis. Kidney Int. 37:335-:335, 1990. 550. Zimmerman, S.W. and Johnson, C.A. Rifampin use in peritoneal dialysis. Perit.Dial.Int. 9:241-243:241-243, 1989.